C:\STNEXP4\QUERIES\10072534.str





chain nodes :
6 13 14 15
ring nodes :
1 2 3 4 5 7 8 9 10 11 12
chain bonds :
2-7 3-6 5-13 13-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-5 2-3 2-7 3-4 3-6 4-5 13-14
exact bonds :
5-13
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12

G1:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom 16:CLASS
Generic attributes :
15:
Type of Ring System : Polycyclic

Element Count :
Node 15: Limited
N,N1

```
=> d his

     (FILE 'HOME' ENTERED AT 10:43:37 ON 07 JAN 2004)

     FILE 'REGISTRY' ENTERED AT 10:43:45 ON 07 JAN 2004
L1             STRUCTURE UPLOADED
L2             QUE L1
L3              21 S L2
L4             498 S L2 SSS FUL

     FILE 'CAPLUS' ENTERED AT 10:44:46 ON 07 JAN 2004
L5              37 S L4

     FILE 'REGISTRY' ENTERED AT 10:45:08 ON 07 JAN 2004

     FILE 'CAPLUS' ENTERED AT 10:48:03 ON 07 JAN 2004

     FILE 'REGISTRY' ENTERED AT 10:48:34 ON 07 JAN 2004

     FILE 'CAPLUS' ENTERED AT 10:50:17 ON 07 JAN 2004

=> d l2
L2 HAS NO ANSWERS
L1             STR
```




```
G1 O,N


Structure attributes must be viewed using STN Express query preparation.
L2             QUE  ABB=ON  PLU=ON  L1


=> d ibib abs hitstr 1-37
```

L5 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:991334 CAPLUS
TITLE: Methods of treating Alzheimer's disease using and method of preparing .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides
INVENTOR(S): John, Varghese; Maillard, Michel
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103653	A1	20031218	WO 2003-US18517	20030611

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-387880P P 20020611
GI



I

AB Disclosed are methods for treating Alzheimer's disease (no data), and other diseases (no data), and/or inhibiting beta-secretase enzyme (no data), and/or inhibiting deposition of A beta peptide in a mammal (no data), using .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides (shown as I; variables defined below; e.g. 2(R,S)-methyl-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(p-tert-butylphenyl)octanoic acid N-butylamide hydrochloride). For I: R1 = H, OH, alkoxy, cycloalkoxy, alkoxyalkoxy, free or amidated or esterified carboxy-alkoxy; R2 = H, alkyl, cycloalkyl, alkoxyalkyl, cycloalkoxyalkyl, OH, hydroxyalkoxy, heteroarylalkyl, etc.; R3 = halogenated alkyl, alkoxyalkyl, hydroxyalkyl, optionally S-oxidized alkylthioalkyl, etc.; R4 = H, alkyl, OH, alkoxy,

L5 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
azaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 172966-87-9 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-oxa-4,8-diazaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172966-90-4 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[2-[(methoxymethoxy)methyl]-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
cycloalkoxy; X = CH2; R5 = alkyl, cycloalkyl; R6 = unsubstituted or alkylated or alkanoylated amino; R7 = alkyl, alkenyl, cycloalkyl, aralkyl; R8 = alkyl, cycloalkyl, free or esterified or etherified hydroxyalkyl, free or esterified or amidated carboxyalkyl, etc. Although the methods of prepn. are claimed and >180 example prepns. are included, these examples comprise an English translation of a German patent (EP 678503; 1995; CA file accession no. 1995:995373). Thus, 2(R,S)-methyl-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(p-tert-butylphenyl)octanoic acid N-butylamide hydrochloride was prepd. in several steps starting with 3-isovaleryl-4(R)-benzyloxazolidin-2-one and p-tert-butylbenzyl bromide.
IT INDEXING IN PROGRESS
IT **172966-59-5P 172966-65-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treating Alzheimer's disease using and method of prepg. .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides)
RN 172966-59-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172966-65-3 CAPLUS
CN 1,4-Dioxa-8-azaspiro[4.5]decane-6-carboxylic acid, 8-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **172966-85-7P 172966-87-9P 172966-90-4P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treating Alzheimer's disease using and method of prepg. .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides)
RN 172966-85-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[2-(hydroxymethyl)-1,4-dioxa-8-

DE ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:892834 CAPLUS
DOCUMENT NUMBER: 139:365764
TITLE: Diblock copolymers for use in pharmaceutical dosage forms
INVENTOR(S): Arieen, Albertina Maria Eduarda; Brewster, Marcus Eli; Nathan, Aruna; Rosenblatt, Joel; Ould-Ouali, Louisa Myriam; Preat, Veronique
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093344	A1	20031113	WO 2003-EP4368	20030424

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-377901P P 20020503
AB In a diblock copolymer of formula A-B, polymer block A represents a linear pharmaceutically acceptable hydrophilic polymer and polymer block B represents a polymer comprising monomers selected from L-lactic acid, D-lactic acid, D,L-lactic acid, glycolic acid, propiolactone, .gamma.-butyrolactone, .delta.-valerolactone, .gamma.-valerolactone, .epsilon.-caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, .epsilon.-lactone, 1,5-dioxepan-2-one or mixts. thereof characterized in that the diblock copolymer is liq. at a temp. below 50.degree.. A polymer was prepd. from .epsilon.-caprolactone, trimethylene carbonate, and polyethylene glycol monomethyl ether initiator.
IT **474016-05-2**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diblock copolymers for use in pharmaceutical dosage forms)
RN 474016-05-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2,6-dihydro-2-methylpyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:696875 CAPLUS
DOCUMENT NUMBER: 139:214457
TITLE: Preparation of 3-aryl-2-oxo-5-oxazolidinecarboxamides and analogs as antibacterial agents
INVENTOR(S): Thomas, Richard C.; Poel, Toni-Jo; Barbachyn, Michael R.; Gordeev, Mikhail F.; Luehr, Gary W.; Renslo, Adam; Singh, Upinder
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 234 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072553	A1	20030904	WO 2003-US3125	20030224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-359495P P 20020225
OTHER SOURCE(S): MARPAT 139:214457
GI



L5 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB Title compds. of formula I, II, and III [wherein B = (un)substituted cycloalkyl, cycloalkenyl, aryl, or heterocyclyl; C = (hetero)aryl (un)substituted with 1-3 R2; or BC = (un)substituted bicyclic heterocycle; R1 = H, OH, cycloalkyl, NH2, or (un)substituted alkyl, alkoxy, or alkenyl; R2 = independently H, NH2, NO2, CN, halo, or (un)substituted alkyl; with provisos; and pharmaceutically acceptable slats thereof] were prepd. as antibacterial agents. Examples include syntheses and biol. data for 91 compds. For instance, benzyl 3-fluoro-4-(4-morpholinyl)phenylcarbamate was stirred with BuLi in THF at -78.degree. for 30 min. Cycloaddn. with potassium (2R)-glycidate gave the 2-oxo-5-oxazolidinecarboxylic acid, which was amidated using oxalyl chloride and ammonium to afford (R)-(-)-IV. Compds. of the invention inhibited growth of Staphylococcus aureus with MIC values ranging from 0.5 .mu.g/mL to 16 .mu.g/mL. Thus, I, II, and III and their pharmaceutical compns. are useful for the treatment of microbial infections.

IT **590421-23-1P**, (5R)-3-[4-(5,7-Dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide **590421-25-3P**, (5R)-N-Methyl-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; prepn. of aryloxazolidinecarboxamides and analogs as antibacterial agents)

RN 590421-23-1 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 590421-25-3 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **590421-24-2P**, Methyl (5R)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of aryloxazolidinecarboxamides and analogs as antibacterial agents)

RN 590421-24-2 CAPLUS
CN 5-Oxazolidinecarboxylic acid, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-, methyl ester, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:633707 CAPLUS
DOCUMENT NUMBER: 139:180089
TITLE: Preparation of antimicrobial thiadiazinone derivatives useful in treatment of bacterial infections
INVENTOR(S): Luehr, Gary W.; Gordeev, Mikhail F.; Patel, Dinesh V.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066631	A1	20030814	WO 2003-US1082	20030204

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-354598P P 20020205
OTHER SOURCE(S): MARPAT 139:180089
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides certain thiadiazinone derivs. of oxazolidinones I [wherein A = G1, G2, G3, or G4; X = O or S; Y = NHCOR1, NHCSR1, NHC(NCN)R1, NH-heterocyclyl, O-heterocyclyl, S-heterocyclyl, heterocyclyl, or OH; R1 = H, NH2, (CH2)rCO-aryl, (CH2)sCO-heterocyclyl, or (un)substituted alkylamino, (hetero)alkyl, alkenyl, (CH2)mCO-alkyl, alkoxy, alkylthio, or (CH2)p-cycloalkyl; R2, R3, R7, and R8 = independently H, Cl, F, Me, NH2, or OH; R4 = H, aryl, heterocyclyl, or (un)substituted (CH2)qCO-alkyl or (CH2)mCO-alkyl; R5 and R6 = independently H, F, aryl, heterocyclyl, or (un)substituted (cyclo)alkyl, heteroalkyl, alkoxy, alkanoyloxy, or alkoxycarbonyl; or CR5R6 = cycloalkyl; m, n, p, q, r, and s = independently 0-2; and their pharmaceutically acceptable salts thereof] as antibacterial agents. Also disclosed are pharmaceutical compns. contg. I, methods for their use, and methods for prepg. the thiadiazinones. For example, base catalyzed condensation of 4-[(R)-5-azidomethyl-2-oxazolidin-3-yl]-2-fluorobenzoic acid with tert-Bu carbazate in DMF gave the hydrazinecarboxylate (99%). Redn. of the azide to the amine using PPh3 in THF (94%), followed by N-protection with di-tert-Bu dicarbonate provided the carbamate (75%). Conversion of the hydrazide into the thiohydrazide using Lawesson's reagent (65%),

L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
alkylation of the thiohydrazide with Me bromoacetate (84%), and deprotection and heterocyclization afforded the [1,3,4]thiadiazin-5-one (99%). Amidation of the 5-(aminomethyl)oxazolidin-2-one with acetic anhydride gave II (76%). Selected compds. of the invention exhibited antimicrobial activity against S. pneumoniae, S. aureus, and H. influenzae with MIC values ranging from <0.06 .mu.g/mL to 2 .mu.g/mL, 0.125 .mu.g/mL to 4 .mu.g/mL, and 0.5 .mu.g/mL to >64 .mu.g/mL, resp.

IT **581064-02-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antimicrobial agent; prepn. of antimicrobial thiadiazinones for treatment of bacterial infections)

RN 581064-02-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(9-oxo-5-thia-7,8-diazaspiro[3.5]non-6-en-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **581064-04-2P**, (S)-6-[4-(5-Aminomethyl-2-oxooxazolidin-3-yl)-2-fluorophenyl]-5-thia-7,8-diazaspiro[3.5]non-6-en-9-one trifluoroacetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of antimicrobial thiadiazinones for treatment of bacterial infections)

RN 581064-04-2 CAPLUS
CN 5-Thia-7,8-diazaspiro[3.5]non-6-en-9-one, 6-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 581064-03-1
CMF C16 H17 F N4 O3 S

Absolute stereochemistry.

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:492705 CAPLUS
DOCUMENT NUMBER: 139:69253
TITLE: Preparation of phenyl oxazolidinone derivatives as potential antimicrobials
INVENTOR(S): Mehta, Anita; Arora, Sudershan K.; Das, Biswajit; Ray, Abhijit; Rudra, Sonali; Rattan, Ashok
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 906,215.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003119817	A1	20030626	US 2002-51784	20020117
US 2002103186	A1	20020801	US 2001-906215	20010716

PRIORITY APPLN. INFO.: US 2001-906215 A2 20010716
IN 2000-DE654 A 20000717
OTHER SOURCE(S): CASREACT 139:69253; MARPAT 139:69253
GI



I



II

AB Substituted Ph oxazolidinones, e.g. of formula I [T = heterocyclic ring, aryl; R = alkyl, halo, CN, CHO, NH2, NO2, etc.; X = CH, CH-S, CH-O, N; Y, Z = H, alkyl, cycloalkyl, bridging group; U, V = alkyl, F, CL, Br, etc.; W = CH2, CO, CH2NH, etc.; R1 = NHCHR2, NR2CSR2; R2 = H, alkyl, cycloalkyl, alkoxy, etc.], are prepd. This invention also relates to pharmaceutical compns. contg. the compds. of the present invention as antimicrobials. The compds. are useful antimicrobial agents, effective against a no. of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. Thus, II was prepd. and showed antibacterial activity against several strains.

IT **392659-55-1P 392659-56-2P 392659-57-3P**
392659-58-4P 392659-59-5P 392659-60-8P
392659-61-9P 392659-62-0P 392659-63-1P
392659-92-6P 392659-93-7P 392659-94-8P

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

392660-87-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of Ph oxazolidinone derivs. as antibacterial agents)

RN 392659-55-1 CAPLUS
CN 3-Furancarboxamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-56-2 CAPLUS
CN 2-Furancarboxamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-5-bromo-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-57-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[methyl[(5-nitro-2-thienyl)methyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 392659-58-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[methyl[(5-nitro-2-furanyl)methyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-59-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[(5-formyl-2-furanyl)methyl]methylamino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 392659-60-8 CAPLUS
CN 2-Furancarboxylic acid, 5-[[[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methylamino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-61-9 CAPLUS
CN 2-Thiopheneacetamide, N-[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-62-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[methyl[(5-nitro-2-thienyl)methyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 392659-63-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[methyl[(5-nitro-2-furanyl)methyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-92-6 CAPLUS
CN 2-Thiopheneacetamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 392659-93-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(5-formyl-2-furanyl)methyl]methylamino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-94-8 CAPLUS
CN 3-Thiophenecarboxamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-87-6 CAPLUS
CN 2-Furancarboxamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **392659-54-0P 392660-02-5P 392660-03-6P**
392660-04-7P 392660-05-8P 392660-06-9P
392660-12-7P 392660-13-8P 392660-14-9P
392660-15-0P 392660-16-1P 392660-17-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of Ph oxazolidinone derivs. as antibacterial agents)

RN 392659-54-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(methylamino)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-02-5 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 392660-03-6 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-[[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-04-7 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-05-8 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-(aminomethyl)-2-

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-06-9 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-12-7 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 392660-13-8 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-[[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-14-9 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-15-0 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 392660-16-1 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-17-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(methylamino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:261821 CAPLUS
DOCUMENT NUMBER: 138:287661
TITLE: Preparation of bicyclo[3.1.0]hexane containing oxazolidinone derivatives for pharmaceutical use as antibiotics
INVENTOR(S): Fukuda, Yasumichi; Hammond, Milton L.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 209 pp.
CODEN: PIXXO2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027083	A1	20030403	WO 2002-US11921	20020417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003125367	A1	20030703	US 2002-123285	20020417

PRIORITY APPLN. INFO.: US 2001-283956P P 20010417
OTHER SOURCE(S): MARPAT 138:287661
GI



AB Oxazolidinones, such as I [R1, R2 = H, CN, CHO, amino, alkyl, aminoalkyl, carboxy, carbamoyl, oxyiminomethyl, etc.; R3 = acylamino, thioacylamino, heterocyclyloxy, etc.; A = C, N; Y = arylene, heteroarylene; n = 0, 1], attached to a bicyclo[3.1.0]hexane, bicyclo[3.1.0]hexene or 3-azabicyclo[3.1.0]hexane moiety were prepd. for therapeutic use and are effective against aerobic and anaerobic pathogens such as multi-resistant

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Staphylococci, Streptococci and Enterococci, Bacteroides, Clostridia, as well as acid-fast organisms such as Mycobacterium tuberculosis, and other mycobacterial species. Thus, N-[5(S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(N-benzyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (II) was prepd. via a multistep synthetic sequence. The prepd. oxazolidinones were tested for antibacterial activity against a variety of strains, such as Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecium.

IT **392659-54-0P 504435-57-8P**, N-[5(S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(N-Benzyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide
504435-58-9P 504435-59-0P 504435-60-3P
504435-62-5P 504435-63-6P 504435-65-8P
504435-67-0P 504435-68-1P 504435-69-2P
504435-70-5P 504435-73-8P 504435-74-9P
504435-75-0P 504435-76-1P 504435-77-2P
504435-79-4P 504435-80-7P 504435-81-8P
504435-83-0P 504435-90-9P 504435-91-0P
504435-93-2P 504435-94-3P 504435-96-5P
504435-99-8P 504436-07-1P 504436-12-8P
504436-14-0P 504436-22-0P 504436-26-4P
504436-27-5P 504436-28-6P 504436-29-7P
504436-30-0P 504436-36-6P 504436-37-7P
504436-45-7P 504436-57-1P 504436-59-3P
504436-60-6P 504436-64-0P 504436-66-2P
504436-67-3P 504436-85-5P 504436-86-6P
504436-87-7P 504436-88-8P 504436-89-9P
504436-90-2P 504436-91-3P 504436-92-4P
504436-94-6P 504436-95-7P 504437-04-1P
504437-05-2P 504437-07-4P 504437-09-6P
504437-11-0P 504437-12-1P 504437-13-2P
504437-22-3P 504437-26-7P 504437-27-8P
504437-33-6P 504437-35-8P 504437-37-0P
504437-38-1P 504437-39-2P 504437-41-6P
504437-43-8P 504437-44-9P, 5-(R)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(N-tert-Butoxycarbonylamino)-3-azabicyclo[3.1.0]hexan-3-yl]phenyl]-5-hydroxymethyloxazolidin-2-one
504437-50-7P 504437-51-8P 504437-60-9P
504437-61-0P 504437-62-1P 504437-63-2P
504437-71-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of bicyclo[3.1.0]hexanyl-oxazolidinones for therapeutic use as antibiotics)

RN 392659-54-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(methylamino)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504435-57-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(phenylmethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-58-9 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 504435-59-0 CAPLUS
CN Acetamide, N-[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-60-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-62-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[methyl(phenylmethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 504435-63-6 CAPLUS
CN Acetamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-65-8 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5S)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-67-0 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504435-68-1 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-[[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-69-2 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504435-74-9 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[[(aminothioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-75-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-76-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504435-70-5 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxoethyl)amino]methyl]-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-73-8 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-(isothiocyanatomethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
{[(tetrahydro-2H-pyran-2-yl)oxy]methyl}-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-77-2 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-79-4 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-80-7 CAPLUS

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(methoxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-81-8 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(methoxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-83-0 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(methoxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(bromomethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-94-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(cyanomethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-96-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504435-90-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-formyl-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-91-0 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-93-2 CAPLUS

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 504435-99-8 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]carbonimidoyl]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-07-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(1-hydroxyethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-12-8 CAPLUS
CN Acetic acid, [[[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methylene]amino]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-14-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-cyano-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-22-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(azidomethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-26-4 CAPLUS

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-29-7 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl](2-azidoethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-30-0 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl][2-[(methylsulfonyl)oxy]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-36-6 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[[(difluoroacetyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(2-hydroxyethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-27-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(2-hydroxyethyl)(phenylmethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-28-6 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl](2-hydroxyethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-37-7 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-45-7 CAPLUS
CN Propanoic acid, 2-[[[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methylene]amino]oxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-57-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-ethenyl-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-59-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-hydroxyethyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-60-6 CAPLUS

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(1,2-dihydroxyethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-64-0 CAPLUS
CN 2-Oxazolidinone, 3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-66-2 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-67-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-85-5 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-[[[tris(1-methylethyl)silyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-86-6 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-[[[tris(1-methylethyl)silyl]oxy]methyl]-, (5R)- (9CI) (CA

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 504436-87-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(bromomethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-5-[[[tris(1-methylethyl)silyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-88-8 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-acetonitrile, 3-[2-fluoro-4-[(5R)-2-oxo-5-[[[tris(1-methylethyl)silyl]oxy]methyl]-3-oxazolidinyl]phenyl]-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 504436-89-9 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-acetonitrile, 3-[2-fluoro-4-[(5R)-2-oxo-5-[[[tris(1-methylethyl)silyl]oxy]methyl]-3-oxazolidinyl]phenyl]-.alpha.-methyl-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-90-2 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-acetonitrile, 3-[2-fluoro-4-[(5R)-2-oxo-5-[[[tris(1-methylethyl)silyl]oxy]methyl]-3-oxazolidinyl]phenyl]-.alpha.,.alpha.-dimethyl-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-91-3 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-acetonitrile, 3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-.alpha.-methyl-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-92-4 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-acetonitrile, 3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-.alpha.-methyl-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-94-6 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-acetonitrile, 3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-.alpha.,.alpha.-dimethyl-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-95-7 CAPLUS

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Azabicyclo[3.1.0]hexane-6-acetonitrile, 3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-.alpha.-methyl-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-04-1 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-05-2 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2,6-difluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 504437-07-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-09-6 CAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-11-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504437-12-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-formyl-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-13-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(hydroxyimino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504437-33-6 CAPLUS
CN Carbamic acid, [[(5R)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-35-8 CAPLUS
CN Carbamic acid, [[(5R)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1,2,4-oxadiazol-3-yl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-37-0 CAPLUS

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 504437-22-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-26-7 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-27-8 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(phenylmethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-(hydroxymethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-38-1 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2,6-difluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-39-2 CAPLUS
CN Carbamic acid, [[(5R)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1,2,4-oxadiazol-3-yl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504437-41-6 CAPLUS
CN Carbamic acid, [[(5R)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-43-8 CAPLUS
CN Carbamic acid, [[(5R)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 504437-51-8 CAPLUS
CN Carbamic acid, [[(5R)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-cyano-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-60-9 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5R)-5-[(acetyloxy)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-61-0 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504437-44-9 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-50-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[4-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504437-62-1 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5R)-5-[[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-63-2 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-71-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[1-cyano-2-

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(dimethylamino)ethenyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT **504435-61-4P 504435-64-7P 504435-71-6P**
504435-72-7P 504435-84-1P 504435-85-2P
504435-86-3P 504435-87-4P 504435-88-5P
504435-89-6P 504435-92-1P 504435-95-4P
504435-97-6P 504435-98-7P 504436-00-4P
504436-01-5P 504436-02-6P 504436-03-7P
504436-04-8P 504436-05-9P 504436-06-0P
504436-08-2P 504436-09-3P 504436-10-6P
504436-11-7P 504436-13-9P 504436-23-1P
504436-24-2P 504436-25-3P 504436-31-1P
504436-32-2P 504436-33-3P 504436-34-4P
504436-35-5P 504436-38-8P 504436-39-9P
504436-40-2P 504436-41-3P 504436-44-6P
504436-47-9P 504436-48-0P 504436-50-4P
504436-51-5P 504436-52-6P 504436-54-8P
504436-56-0P 504436-58-2P 504436-61-7P
504436-62-8P 504436-63-9P 504436-68-4P
504436-70-8P 504436-73-1P 504436-84-4P
504436-93-5P 504437-00-7P 504437-08-5P
504437-14-3P 504437-15-4P 504437-16-5P
504437-17-6P 504437-18-7P 504437-19-8P
504437-23-4P 504437-24-5P 504437-25-6P
504437-28-9P 504437-32-5P 504437-34-7P
504437-36-9P 504437-40-5P 504437-42-7P
504437-53-0P 504437-54-1P 504437-58-5P
504437-72-3P 504438-38-4P 504438-39-5P
504438-40-8P 504438-41-9P 504438-42-0P
504438-43-1P 504438-44-2P 505028-19-3P
505048-67-9P 505049-93-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bicyclo[3.1.0]hexanyl-oxazolidinones for therapeutic use as antibiotics)

RN 504435-61-4 CAPLUS
CN Acetamide, N-[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504435-72-7 CAPLUS
CN Thiourea, [[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(phenylmethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-84-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(3-isoxazolyloxy)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-85-2 CAPLUS

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-64-7 CAPLUS
CN Acetamide, N-[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-71-6 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(phenylmethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(acetylamino)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-86-3 CAPLUS
CN Benzamide, N-[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-87-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(phenylsulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 504435-88-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(methylsulfonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-89-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(aminocarbonyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504435-92-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(1-iminoethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504435-95-4 CAPLUS
CN Pyridinium, 1-[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, bromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 504435-97-6 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carboxamide, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504435-98-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, methyl ester, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-00-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(aminoiminomethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-01-5 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carboxamide, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-methyl-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.



RN 504436-02-6 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carboxamide, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N,N-dimethyl-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-03-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(1-piperidinylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-04-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(4-morpholinylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 504436-05-9 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carboxamide, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-(2-hydroxyethyl)-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-06-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(2-aminoethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-11-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(methoxyimino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-13-9 CAPLUS
CN Acetic acid, [[[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methylene]amino]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-23-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(aminomethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 504436-08-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-acetyl-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-09-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(hydroxyimino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 504436-10-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(Z)-(hydroxyimino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-24-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(2-pyridinylamino)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-25-3 CAPLUS
CN Glycine, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-31-1 CAPLUS

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(2-aminoethyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-32-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(3-cyanopyrazinyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-33-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(3-cyano-2-pyridinyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-39-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(2-methoxyethoxy)imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-40-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[2-(dimethylamino)ethoxy]imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-34-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(5-cyano-2-pyridinyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-35-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(2-pyrimidinylamino)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-38-8 CAPLUS

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-41-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[2-(dimethylamino)propoxy]imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-44-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(2-hydroxyethoxy)imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-47-9 CAPLUS
CN Propanoic acid, 2-[[[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
azabicyclo[3.1.0]hex-6-yl]methylene]amino]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-48-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(1H-tetrazol-5-ylmethoxy)imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-50-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(4-morpholinylimino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-51-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(2,3-dihydroxypropoxy)imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-52-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[2-hydroxy-1-(hydroxymethyl)ethoxy]imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 504436-54-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[2-(2-hydroxyethoxy)ethoxy]imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-56-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(cyanomethoxy)imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-58-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(2-hydroxyethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-61-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]acetyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-62-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504436-63-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-hydroxy-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.



RN 504436-68-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[2-(methylthio)ethoxy]imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-70-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[2-(methylsulfinyl)ethoxy]imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 504436-93-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(1-cyano-1-methylethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-00-7 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-cyano-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-08-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504436-73-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[2-(methylsulfonyl)ethoxy]imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504436-84-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(1-cyanoethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504437-14-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-cyano-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-15-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(cyanomethyl)-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-16-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(2,3-dihydroxypropoxy)imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry unknown.



RN 504437-17-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(2-hydroxyethoxy)imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504437-18-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[2-(2-hydroxyethoxy)ethoxy]imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504437-19-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[2-hydroxy-1-(hydroxymethyl)ethoxy]imino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 504437-23-4 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 504437-24-5 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(3-isoxazolyloxy)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-25-6 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(methoxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-28-9 CAPLUS
CN 2-Oxazolidinone, 3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504437-32-5 CAPLUS
CN 2-Oxazolidinone, 3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-34-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-5-[(1,2,4-oxadiazol-3-ylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-36-9 CAPLUS
CN 2-Oxazolidinone, 3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-5-[(1,2,4-oxadiazol-3-ylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-40-5 CAPLUS
CN 2-Oxazolidinone, 3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-42-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504437-53-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[1-(cyanoamino)ethylidene]amino]-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-54-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(5-amino-4-cyano-2-oxazolyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 504437-58-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504437-72-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-(3-amino-1H-pyrazol-4-yl)-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504438-38-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(4-amino-2-pyrimidinyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 504438-39-5 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504438-40-8 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[2-fluoro-4-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504438-41-9 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[2-fluoro-4-[(5S)-5-[(1,2,4-oxadiazol-3-ylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504438-42-0 CAPLUS
CN 2-Oxazolidinone, 3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-5-[(2-pyridinylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 504438-43-1 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[4-[(5S)-5-[(1,2,4-oxadiazol-3-ylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 505048-67-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1R,5S)-6-[(E)-amino(hydroxyimino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 505049-93-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1R,5S)-6-[(Z)-amino(hydroxyimino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 504438-44-2 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[4-[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, (1.alpha.,5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 505028-19-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1.alpha.,5.alpha.,6.alpha.)-6-cyano-3-oxido-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:5775 CAPLUS
DOCUMENT NUMBER: 138:89797
TITLE: Preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases
INVENTOR(S): Straub, Alexander; Lampe, Thomas; Pernerstorfer, Josef; Perzborn, Elisabeth; Pohlmann, Jens; Roehrig, Susanne; Schlemmer, Karl-Heinz
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000256	A1	20030103	WO 2002-EP6237	20020607
WO 2003000256	C2	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10129725	A1	20030102	DE 2001-10129725	20010620

PRIORITY APPLN. INFO.: DE 2001-10129725 A 20010620
OTHER SOURCE(S): MARPAT 138:89797
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to combinations of (A) oxazolidinones I [R1 = 5-X-2-thienyl (X = Cl, Br, Me, CF3); R2 = DA; A = phenylene; D = 5- or 6-membered heterocyclic ring contg. S, N or O; R4 - R8 = H], or their pharmaceutically acceptable salts, hydrates, prodrugs or their mixts. and (B) other pharmaceutically active ingredients; to a method for producing said combinations; and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases. Thus, the claimed oxazolone II was prepd. from epoxide III via epoxide ring opening with aniline deriv. IV, cyclization with carbonyldiimidazole, and N-acylation with 5-chlorothiophene-2-sulfonyl chloride. II was tested for antithrombotic activity in the arteriovenous shunt model (Rat) after [ED50 = 3 mg/kg (p.o.); IC50 = 0.7 nM]; II had a synergistic effect when used in combination with clopidogrel.

IT **482306-46-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and pharmacol. activity of; prepn. of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases)

L5 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 482306-46-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[3-[4-(hexahydro-2-methyl-5H-pyrrolo[3,4-d]isoxazol-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:833517 CAPLUS
DOCUMENT NUMBER: 137:337913
TITLE: Synthesis and use of heterobicyclic substituted phenyl oxazolidinones as antibacterial agents
INVENTOR(S): Paget, Steven D.; Hlasta, Dennis J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 50 pp., Cont.-in-part of U.S. 6,413,981.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161029	A1	20021031	US 2002-58841	20020128
US 6608081	B2	20030819		
US 6413981	B1	20020702	US 2000-621814	20000721
US 2003171366	A1	20030911	US 2002-43747	20020110
WO 2003064415	A1	20030807	WO 2003-US1673	20030121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-148621P P 19990812
US 2000-621814 A2 20000721
US 2002-58841 A 20020128
OTHER SOURCE(S): MARPAT 137:337913
GI

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB The title compds. [I; R = OH, N3, oxy(hetero)aryl, etc.; X = 0-4 members chosen from halo, OH, NO2, etc.; Y = 1,3-dihydro-1-oxo-2H-isoindol-2-yl, 1,3-dihydro-2H-isoindol-2-yl, 1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl, etc.] are claimed. One-hundred-twenty-one synthetic examples are provided. For example, the product of the substitution reaction between isoindoline and 3,4-difluoronitrobenzene was reduced to the corresponding amine. The amine was converted to the benzyloxycarbonyl deriv., deprotonated with n-BuLi and treated with (R)-glycidyl butyrate to give the oxazolidinone alc. Conversion of the alc. to amide II proceeded in 3 steps. Compds. I were tested against S. aureus (OC4172), E. faecium (OC3312) and MRSA (OC2878, methicillin resistant Staphylococcus aureus). MIC values ranged from 1 to .gtoreq.128 .mu.g/mL for exemplified compds. I. Compd. II had MIC of 2 .mu.g/mL in all strains tested.

IT **344459-84-3P 344459-92-3P 344460-22-6P 474016-08-5P 474016-37-0P 474017-60-2P 474017-63-5P 474017-80-6P 474018-11-6P 474018-28-5P 474018-42-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. and use of heterobicyclic substituted Ph oxazolidinones as antibacterial agents)

RN 344459-84-3 CAPLUS
CN Carbamimidothioic acid, N-cyano-N'-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-92-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-22-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-08-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-(cyanomethyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474016-37-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(2-hydroxyethyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-60-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(2S)-oxiranylmethyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-63-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(2R)-oxiranylmethyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474018-42-3 CAPLUS
CN L-Valine, N-[(phenylmethoxy)carbonyl]-, 2-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

IT 344459-50-3P 344459-52-5P 344459-54-7P
344459-56-9P 344459-57-0P 344459-59-2P
344459-61-6P 344459-62-7P 344459-63-8P
344459-65-0P 344459-66-1P 344459-67-2P
344459-68-3P 344459-69-4P 344459-70-7P
344459-72-9P 344459-74-1P 344459-76-3P
344459-78-5P 344459-80-9P 344459-82-1P
344459-86-5P 344459-88-7P 344459-90-1P
344459-94-5P 344459-96-7P 344459-97-8P
344459-98-9P 344460-00-0P 344460-01-1P
344460-03-3P 344460-05-5P 344460-07-7P
344460-09-9P 344460-11-3P 344460-13-5P
344460-14-6P 344460-15-7P 344460-17-9P
344460-18-0P 344460-20-4P 344460-26-0P
344460-28-2P 344460-30-6P 344460-33-9P
474015-84-4P 474015-87-7P 474015-90-2P
474015-95-7P 474015-99-1P 474016-02-9P
474016-05-2P 474016-10-9P 474016-13-2P
474016-15-4P 474016-18-7P 474016-22-3P
474016-28-9P 474016-33-6P 474016-42-7P
474016-47-2P 474016-53-0P 474016-58-5P

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474017-80-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-[(2S)-3-(ethylthio)-2-hydroxypropyl]-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-11-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(methylthio)methyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-28-5 CAPLUS
CN Phosphoric acid, 2-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

474016-63-2P 474016-69-8P 474016-74-5P
474016-80-3P 474016-85-8P 474016-90-5P
474016-95-0P 474017-00-0P 474017-04-4P
474017-13-5P 474017-16-8P 474017-19-1P
474017-22-6P 474017-25-9P 474017-29-3P
474017-32-8P 474017-35-1P 474017-39-5P
474017-43-1P 474017-47-5P 474017-51-1P
474017-54-4P 474017-57-7P 474017-66-8P
474017-69-1P 474017-72-6P 474017-76-0P
474017-84-0P 474017-88-4P 474017-90-8P
474017-94-2P 474017-98-6P 474018-01-4P
474018-05-8P 474018-08-1P 474018-14-9P
474018-18-3P 474018-20-7P 474018-23-0P
474018-25-2P 474018-30-9P 474018-33-2P
474018-36-5P 474018-39-8P 474018-45-6P
474018-49-0P 474018-71-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and use of heterobicyclic substituted Ph oxazolidinones as antibacterial agents)

RN 344459-50-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-52-5 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-54-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-56-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-57-0 CAPLUS
CN Acetamide, N-[[(5R)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-59-2 CAPLUS
CN Acetamide, N-[[(5R)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
fluorophenyl]-5-[(pyrazinyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-65-0 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-5-[(pyrazinyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-66-1 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-67-2 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 344459-61-6 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-62-7 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-63-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 344459-68-3 CAPLUS
CN Propanamide, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-69-4 CAPLUS
CN Propanamide, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-70-7 CAPLUS
CN Cyclopropanecarboxamide, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 344459-72-9 CAPLUS
CN Cyclopropanecarboxamide, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-74-1 CAPLUS
CN Carbamic acid, [[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 344459-80-9 CAPLUS
CN Methanesulfonamide, N-[[(5R)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-82-1 CAPLUS
CN Methanesulfonamide, N-[[(5R)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-86-5 CAPLUS
CN Carbamimidothioic acid, N-cyano-N'-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-76-3 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-78-5 CAPLUS
CN Carbamic acid, [[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-88-7 CAPLUS
CN Guanidine, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-90-1 CAPLUS
CN Guanidine, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-94-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(5-oxido-2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 344459-96-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-97-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-5-[(3-isothiazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-98-9 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl]-5-[(3-isothiazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 344460-03-3 CAPLUS
CN Propanamide, N-[[(5S)-3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-05-5 CAPLUS
CN Cyclopropanecarboxamide, N-[[(5S)-3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-07-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-2-methyl-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-09-9 CAPLUS

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 344460-00-0 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-01-1 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-11-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-d]pyrimidin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-13-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-2-pyrazinyl-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-14-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(2-pyrazinyl-6H-pyrrolo[3,4-d]pyrimidin-

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-15-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(3-oxido-2-pyrazinyl-6H-pyrrolo[3,4-d]pyrimidin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-17-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[5,7-dihydro-2-(4-pyridinyl)-6H-pyrrolo[3,4-d]pyrimidin-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-18-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[5,7-dihydro-2-(2-pyridinyl)-6H-pyrrolo[3,4-d]pyrimidin-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-20-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[5,7-dihydro-2-(3-pyridinyl)-6H-pyrrolo[3,4-d]pyrimidin-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-26-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-28-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-30-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-7-oxo-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-33-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-5-oxo-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474015-84-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(4,6-dihydro-1-methylpyrrolo[3,4-c]pyrazol-5(1H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474015-87-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(2-pyridinyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474015-90-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[1-(1,1-dimethylethyl)-4,6-dihydropyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474015-95-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4,6-dihydro-1-(2-hydroxyethyl)pyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474015-99-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[1-[2-(diethylamino)ethyl]-4,6-dihydropyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474016-02-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-[2-(diethylamino)ethyl]-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-05-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2,6-dihydro-2-methylpyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-10-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2,6-dihydro-2-pyrazinylpyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474016-13-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(2-pyrimidinyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-15-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[1-[2-(dimethylamino)ethyl]-4,6-dihydropyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-18-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-[2-(dimethylamino)ethyl]-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474016-22-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2-ethyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-28-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[2-(4-morpholinyl)ethyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-33-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4,6-dihydro-1-[2-(4-morpholinyl)ethyl]pyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474016-42-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-[(2S)-2,3-dihydroxypropyl]-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-47-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(2-propynyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-53-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(3-hydroxypropyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 474016-74-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-(cyclopropylmethyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-80-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[1-(cyclopropylmethyl)-4,6-dihydropyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-85-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(2-oxopropyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



RN 474016-58-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-[(2R)-2,3-dihydroxypropyl]-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-63-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(2,2,2-trifluoroethyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-69-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(phenylmethyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474016-90-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(2-oxo-5-oxazolidinyl)methyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474016-95-0 CAPLUS
CN Pyrrolo[3,4-c]pyrazole-1(4H)-acetic acid, 5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-00-0 CAPLUS
CN Pyrrolo[3,4-c]pyrazole-2(4H)-acetic acid, 5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474017-04-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4,6-dihydro-1-(2-propynyl)pyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-13-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(1,2-propadienyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-16-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4,6-dihydro-1-(1,2-propadienyl)pyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474017-19-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4,6-dihydro-1-[(trimethylsilyl)methyl]pyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-22-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(trimethylsilyl)methyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-25-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[1-[(dimethylphenylsilyl)methyl]-4,6-dihydropyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474017-29-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-[(dimethylphenylsilyl)methyl]-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-32-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4,6-dihydro-1-[(phenylmethoxy)methyl]pyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-35-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(phenylmethoxy)methyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474017-39-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(methylamino)thioxomethyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-43-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(1H-tetrazol-5-ylmethyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-47-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(3-pyridinylmethyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474017-51-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(2-pyridinylmethyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-54-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4,6-dihydro-1-(2-pyridinylmethyl)pyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-57-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(2-propenyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 474017-76-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(2S)-2-hydroxy-3-(phenylthio)propyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-84-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(2S)-2-hydroxy-3-[(2-hydroxyethyl)thio]propyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-88-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-(1-methylethyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 474017-66-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-(2-cyanoethyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-69-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(2R)-2-hydroxy-3-(1-piperidinyl)propyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-72-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474017-90-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-(2-aminoethyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-94-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-[(2R)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474017-98-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-[(2S)-3-(ethylsulfinyl)-2-hydroxypropyl]-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474018-01-4 CAPLUS
CN Phosphoric acid, 2-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl]ethyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-05-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[2-(4-thiomorpholinyl)ethyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-08-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4,6-dihydro-1-[(methylthio)methyl]pyrrolo[3,4-c]pyrazol-5(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474018-23-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[[(R)-methylsulfinyl]methyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-25-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[[(S)-methylsulfinyl]methyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-30-9 CAPLUS
CN Benzoic acid, 4-(4-morpholinylmethyl)-, 2-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474018-14-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(methylsulfonyl)methyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-18-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[2-(methylthio)ethyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-20-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[2-(methylsulfonyl)ethyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 474018-33-2 CAPLUS
CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 474018-36-5 CAPLUS
CN Benzoic acid, 4-[(4-methyl-1-piperazinyl)methyl]-, 2-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 474018-39-8 CAPLUS
CN Glycine, N,N-dimethyl-, 2-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-45-6 CAPLUS
CN L-Valine, 2-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474018-49-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[2-(phosphonooxy)ethyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]tetrahydro-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-71-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(4,6-dihydro-1-propylpyrrolo[3,4-c]pyrazol-5(1H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **250372-40-8P 250372-93-1P 250373-26-3P**
250373-69-4P 344460-45-3P 344460-46-4P
344460-47-5P 344460-49-7P 344460-51-1P
474018-53-6P 474018-57-0P 474018-61-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and use of heterobicyclic substituted Ph oxazolidinones as antibacterial agents)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 250372-40-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250372-93-1 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250373-26-3 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250373-69-4 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry. Rotation (-).



RN 344460-45-3 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-46-4 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-47-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-49-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-51-1 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-53-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[2-[(methylsulfonyl)oxy]ethyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-57-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474018-61-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[2,6-dihydro-2-[(2R)-2-hydroxy-3-(4-thiomorpholinyl)propyl]pyrrolo[3,4-c]pyrazol-5(4H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



applicant's

L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:637662 CAPLUS
DOCUMENT NUMBER: 137:185482
TITLE: Preparation of isoquinolinylphenyloxazolidinone antibacterials
INVENTOR(S): Paget, Steven D.; Weidner-Wells, Michele A.; Werblood, Harvey M.
PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064574	A2	20020822	WO 2002-US3982	20020206
WO 2002064574	A3	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003176422	A1	20030918	US 2002-72534	20020206
EP 1358185	A2	20031105	EP 2002-726571	20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-266938P P 20010207
WO 2002-US3982 W 20020206
OTHER SOURCE(S): MARPAT 137:185482
GI



AB Oxazolidinones I [R = OH, N3, OCH2Ph, acyloxy, aryloxy, heteroaryloxy, O3SR2, (un)substituted NH2; R1 = substituted Ph; R2 = Ph, tolyl, alkyl] were prepd. for use as antibacterial agents, particularly against antibiotic-resistant gram pos. organisms. Thus, 1,2,3,4-tetrahydroisoquinoline was N-substituted with 3,4-F2C6H3NO2, reduced to the amine, N-benzyloxycarbonylated, and treated with (R)-glycidyl butyrate to give the alc. II [R = OH] which was mesylated, treated with K phthalimide, hydrolyzed, and N-acetylated to give II [R = NHAc]. II [R = NHAc] had min. inhibitory concns. of Staphylococcus aureus OC4172 8, S. aureus OC2878 4, and Enterococcus faecium OC3312 8 .mu.g/mL.

L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

IT **449175-14-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of isoquinolinylphenyloxazolidinone antibacterials)
RN 449175-14-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(3,4-dihydro-2(1H)-isoquinolinyl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **449175-15-9P 449175-16-0P 449175-17-1P**
449175-18-2P 449175-19-3P 449175-20-6P
449175-21-7P 449175-22-8P 449175-23-9P
449175-24-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of isoquinolinylphenyloxazolidinone antibacterials)
RN 449175-15-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(3,4-dihydro-2(1H)-isoquinolinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-16-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 449175-17-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(3,4-dihydro-1-oxo-2,6-naphthyridin-2(1H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-18-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-19-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(7,8-dihydro-2-methylpyrido[4,3-d]pyrimidin-6(5H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 449175-22-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(7,8-dihydro-2-pyrazinylpyrido[4,3-d]pyrimidin-6(5H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-23-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-24-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1,4,6,7-tetrahydro-1-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 449175-20-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[7,8-dihydro-2-(2-methyl-4-thiazolyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-21-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[7,8-dihydro-2-(4-pyridinyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **449175-29-5P 449175-36-4P 449175-37-5P**
449175-38-6P 449175-39-7P 449175-40-0P
449175-47-7P 449175-48-8P 449175-49-9P
449175-51-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of isoquinolinylphenyloxazolidinone antibacterials)

RN 449175-29-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(3,4-dihydro-2(1H)-isoquinolinyl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-36-4 CAPLUS
CN 2-Oxazolidinone, 3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-37-5 CAPLUS
CN 2-Oxazolidinone, 3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-

L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-38-6 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-39-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-5-[[(triphenylphosphoranylidene)amino]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 449175-49-9 CAPLUS
CN 2,6-Naphthyridin-1(2H)-one, 2-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-51-3 CAPLUS
CN 2-Oxazolidinone, 3-[4-(3,4-dihydro-2(1H)-isoquinolinyl)-3-fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 449175-40-0 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-47-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-48-8 CAPLUS
CN 2,6-Naphthyridin-1(2H)-one, 2-[2-fluoro-4-[(5R)-5-[[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:575074 CAPLUS
DOCUMENT NUMBER: 137:125148
TITLE: Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
INVENTOR(S): Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059116	A2	20020801	WO 2001-US44731	20011129
WO 2002059116	A3	20021205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003013737	A1	20030116	US 2001-996927	20011129
EP 1349853	A2	20031008	EP 2001-994117	20011129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-257904P P 20001221
WO 2001-US44731 W 20011129
OTHER SOURCE(S): MARPAT 137:125148
GI



I



II

L5 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB Substituted quinolones I [Y1 = CH, N; Y2, Y3 = C, N; R1 = H, alkyl, cycloalkyl, haloalkyl, halophenyl, LXmQ; R2 = H, alkyl, alkoxy, halo, haloalkoxy; R1R2 = atoms required to complete an (un)substituted 5-6-membered heterocyclic or heteroarom. ring; R3 = H, F; R4 = H, Me, NH2, F; R5 = H, LXmQ; L = bond, (un)substituted NH, NH(CH2)nNH; X = (un)substituted p-C6H4, 2,5-pyridinediyl; Q = Q1, Q2, Q3; m = 0, 1; n = 0-3; R6 = OH, alkoxy, aryloxy, acylamino] were prepd. The quinolone derivs. possess antibacterial activity, and are effective against a no. of human and veterinary pathogens in the treatment of bacterial diseases. Thus, the quinolone II was prepd. from the 7-chloroquinolone and the piperazine fragments. II had min. inhibitory concs. against E. faecalis 0.25, S. aureus 0.5, S. pneumoniae 0.125, H. influenzae 8, M. catarrhalis 1, and E. coli 16 .mu.g/mL.

IT **444335-22-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antimicrobial quinolone derivs. and their use to treat bacterial infections)

RN 444335-22-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **444335-20-0P 444335-21-1P 444335-23-3P**
444335-26-6P 444335-40-4P 444335-41-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of antimicrobial quinolone derivs. and their use to treat bacterial infections)

RN 444335-20-0 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 444335-26-6 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 444335-25-5
CMF C25 H23 F2 N3 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 444335-40-4 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-(3-acetyl-6,7-difluoro-4-oxo-1(4H)-quinolinyl)-3-

L5 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 444335-21-1 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-23-3 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-41-5 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **444335-24-4P 444335-42-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antimicrobial quinolone derivs. and their use to treat bacterial infections)

RN 444335-24-4 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-,

L5 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-42-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:504766 CAPLUS
DOCUMENT NUMBER: 137:78944
TITLE: Preparation of aryloxazolones as antibacterials.
INVENTOR(S): Natesan, Selvakumar; Das, Jagattaran; Iqbal, Javed; Magadi, Sitaram Kumar; Mamidi, Naga Venkata Srinivasa Rao; Ramanujam, Rajagopalan; Sundarababu, Baskaran; Lohray, Braj Bhushan
PATENT ASSIGNEE(S): Dr. Reddy's Research Foundation, India; Dr. Reddy's Laboratories Ltd.
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051819	A2	20020704	WO 2001-IN227	20011226
WO 2002051819	A3	20021205		
WO 2002051819	C2	20030807		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003065175	A1	20030403	US 2001-32392	20011221
EP 1345913	A2	20030924	EP 2001-995805	20011226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300254	A	20031215	EE 2003-254	20011226
NO 2003002926	A	20030825	NO 2003-2926	20030625

PRIORITY APPLN. INFO.:
IN 2000-MA1124 A 20001226
IN 2001-MA15 A 20010115
IN 2000-CH1124 A 20001226
IN 2001-CH15 A 20010115
WO 2001-IN227 W 20011226

OTHER SOURCE(S): MARPAT 137:78944
GI

L5 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB Title compds. [I: R1 = halo, N3, SCN, SH, OR4, NHR4, N(R4)2; R4 = H, (substituted) acyl, thioacyl, alkoxycarbonyl, cycloalkoxythiocarbonyl, alkenyloxycarbonyl, alkenylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, alkenyloxythiocarbonyl, aryloxythiocarbonyl, COCOA, COCOAr, COCOAlk, COCOArO, CS2A, CSNH2, CSNHA, CSNA2, CSNHAk, CSCOAlk, CSCOArO, CSO2CA, CSCSA, CSCSAr, thiomorpholinylthiocarbonyl, pyrrolidinylthiocarbonyl; A = alkyl; Ar = aryl; Alk = alkoxy; Ak = alkenyl; R2, R3 = H, halo, alkyl, haloalkyl, cyano, nitro, SRa, NRa, ORa; Ra = (substituted) alkyl, haloalkyl; Z = S, O, CH, NRb; Rb = H, (substituted) alkyl, alkenyl, cycloalkyl, alkoxy, aryl, aralkyl, aryloxy, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl; Y1 = O, S; Y2, Y3 = H, halo, cyano, NO2, formyl, OH, amino, O, S, (substituted) alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino, alkoxy, aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl heterocycloalkyl; adjacent Y2Y3 form a (substituted) 5-6 membered arom. or nonarom. cyclic structure, optionally contg. 1-2 heteroatoms], were prepd. Thus, title compd. (II) (general prepn. given) showed a min. inhibitory concn. of 0.25 .mu.g/mL against Staphylococcus aureus 019 MRSA.

IT **439902-61-1P 439902-62-2P 439902-63-3P 439902-68-8P 439902-78-0P 439902-79-1P 439902-84-8P 439903-08-9P 439903-09-0P 439903-10-3P 439903-19-2P 439903-30-7P 439903-68-1P 439903-69-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryloxazolones as antibacterials)

RN 439902-61-1 CAPLUS
CN 2(3H)-Benzoxazolone, 3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 439902-62-2 CAPLUS
CN 2(3H)-Benzoxazolone, 3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439902-63-3 CAPLUS
CN 2(3H)-Benzoxazolone, 3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439902-68-8 CAPLUS
CN 2(3H)-Benzoxazolone, 3-[4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 439902-78-0 CAPLUS
CN 2(3H)-Benzoxazolone, 3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439902-79-1 CAPLUS
CN 2(3H)-Benzoxazolone, 3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439902-84-8 CAPLUS
CN 2(3H)-Benzoxazolone, 3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 439903-19-2 CAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[4-(2-oxo-3(2H)-benzoxazolyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439903-30-7 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(2-oxo-3(2H)-benzoxazolyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439903-68-1 CAPLUS
CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3(2H)-benzoxazolyl)phenyl]-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 439903-08-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(2-oxo-3(2H)-benzoxazolyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439903-09-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(6-methyl-2-oxo-3(2H)-benzoxazolyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439903-10-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(5-methyl-2-oxo-3(2H)-benzoxazolyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 439903-69-2 CAPLUS
CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3(2H)-benzoxazolyl)phenyl]-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:72093 CAPLUS
DOCUMENT NUMBER: 136:134748
TITLE: Oxazolidinone derivatives as antimicrobials
INVENTOR(S): Mehta, Anita; Arora, Sudershan K.; Das, Biswajit; Ray, Abhijit; Rudra, Sonali; Rattan, Ashok
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006278	A1	20020124	WO 2001-IB1262	20010716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001069370	A5	20020130	AU 2001-69370	20010716
EP 1303511	A1	20030423	EP 2001-947730	20010716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012826	A	20030624	BR 2001-12826	20010716
WO 2003008389	A1	20030130	WO 2002-IB167	20020118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003007870	A2	20030130	WO 2002-IB1609	20020510
WO 2003007870	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: IN 2000-DE654 A 20000717
WO 2001-IB1262 W 20010716

L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 136:134748
GI



I



II

AB Oxazolidinones I [T = 5-7-membered heterocyclic ring, acyl; R = CN, acyl, (un)substituted CO2H, NH2, CONH2, alkyl, CH2CH:NOH, CH:CH2, NO2; X = CH, CHS, CHO, N; Y, Z = H, alkyl, cycloalkyl, C0-3 bridging group; U, V = (un)substituted alkyl, H, F, Cl, Br; W = CH2, CO, CH2NH, NHCH2, (un)substituted CH2NHCH2, S, CH2CO, NH; R1 = acylamino, (un)substituted NH2, NHCSR2, NHCS2R2; R2 = H, (un)substituted alkyl, cycloalkyl, alkoxy; n = 0-3] were prepd. The compds. are useful antimicrobial agents, effective against a no. of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. Thus, the furoyl deriv. II was prepd. from the 4-unsubstituted piperdine fragment and furoyl chloride. II had min. inhibitory concns. against methicillin-resistant Staph. aureus 15187 and against Enterococus fecalis 29212 of 2 .mu.g/mL.

IT **392659-55-1P 392659-56-2P 392659-57-3P 392659-61-9P 392659-62-0P 392659-63-1P 392659-92-6P 392659-93-7P 392659-94-8P 392660-87-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azacycloalkylphenyloxazolidinones as antimicrobials)

RN 392659-55-1 CAPLUS
CN 3-Furancarboxamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.



RN 392659-56-2 CAPLUS
CN 2-Furancarboxamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-5-bromo-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-57-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[methyl[(5-nitro-2-thienyl)methyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-61-9 CAPLUS
CN 2-Thiopheneacetamide, N-[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 392659-62-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[methyl[(5-nitro-2-thienyl)methyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-63-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[methyl[(5-nitro-2-furanyl)methyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 392659-92-6 CAPLUS
CN 2-Thiopheneacetamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-93-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[(5-formyl-2-furanyl)methyl]methylamino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-94-8 CAPLUS
CN 3-Thiophenecarboxamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 392660-87-6 CAPLUS
CN 2-Furancarboxamide, N-[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **392659-54-0P 392660-02-5P 392660-03-6P**
392660-04-7P 392660-05-8P 392660-06-9P
392660-12-7P 392660-13-8P 392660-14-9P
392660-15-0P 392660-16-1P 392660-17-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azacycloalkylphenyloxazolidinones as antimicrobials)
RN 392659-54-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-(methylamino)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 392660-02-5 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-03-6 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-[[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-04-7 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5R)-5-(azidomethyl)-2-

L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-05-8 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-06-9 CAPLUS
CN Carbamic acid, [(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 392660-12-7 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-13-8 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[2-fluoro-4-[(5R)-5-[[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-14-9 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 392660-15-0 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-16-1 CAPLUS
CN Carbamic acid, [[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 392660-17-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[(methylamino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **392659-58-4P 392659-59-5P 392659-60-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azacycloalkylphenyloxazolidinones as antimicrobials)
RN 392659-58-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[methyl[(5-nitro-2-furanyl)methyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-59-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1.alpha.,5.alpha.,6.alpha.)-6-[[[(5-formyl-2-furanyl)methyl]methylamino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 392659-60-8 CAPLUS
CN 2-Furancarboxylic acid, 5-[[[[(1.alpha.,5.alpha.,6.alpha.)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methylamino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:798227 CAPLUS
DOCUMENT NUMBER: 135:344473
TITLE: Oxazolidinone derivatives with antibacterial activity
INVENTOR(S): Gravestock, Michael Barry; Betts, Michael John; Griffin, David Alan; Matthews, Ian Richard
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081350	A1	20011101	WO 2001-GB1815	20010423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2001010240	A	20030107	BR 2001-10240	20010423
EP 1286998	A1	20030305	EP 2001-921669	20010423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531211	T2	20031021	JP 2001-578439	20010423
NO 2002005091	A	20021209	NO 2002-5091	20021023
US 2003216373	A1	20031120	US 2003-258355	20030506

PRIORITY APPLN. INFO.: GB 2000-9803 A 20000425
WO 2001-GB1815 W 20010423
OTHER SOURCE(S): MARPAT 135:344473
GI

L5 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. [I; X = O, NH, S, etc.; HET = (un)substituted C-linked 5-membered heteroaryl ring contg. 2-4 heteroatoms selected from N, O and S, etc.; Q = II, III, etc. (wherein R2, R3 = H, F; T = an N-linked (fully unsatd.) 5-membered heteroaryl ring system or IV; Rc = R13CO, R13SO2, R13CS, etc.; R13 = alkyl, etc.)], useful as antibacterial agents, were prepd. and formulated. E.g., a multi-step synthesis of the oxazoline (R)-V which showed MIC of 0.125 .mu.g/mL against Staphylococcus aureus (Oxford), was given.

IT **172967-24-7P 172967-25-8P 371195-28-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(oxazolidinone derivs. with antibacterial activity)

RN 172967-24-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172967-25-8 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.



RN 371195-28-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:482178 CAPLUS
DOCUMENT NUMBER: 135:76881
TITLE: Preparation of N-(oxooxazolidinylmethyl)thioamides and analogs as bactericides
INVENTOR(S): Hester, Jackson B., Jr.; Nidy, Eldon George; Perricone, Salvatore Charles; Poel, Toni-Jo
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: U.S., 93 pp., Cont.-in-part of U.S. 6,218,413.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6255304	B1	20010703	US 1998-200904	19981127
US 6218413	B1	20010417	US 1998-80751	19980518
US 6362189	B1	20020326	US 2000-712055	20001114
US 6342513	B1	20020129	US 2000-713739	20001115
US 2001041728	A1	20011115	US 2001-822072	20010330
US 6537986	B2	20030325		
US 2002016323	A1	20020207	US 2001-822666	20010330

PRIORITY APPLN. INFO.: US 1997-48342P P 19970530
US 1998-80751 A2 19980518
US 1998-200904 A3 19981127
OTHER SOURCE(S): MARPAT 135:76881
GI



AB RZZ1CH2NHCSR1 [I; R = e.g., N-attached-(oxo)thiaazacycloalkyl; R1 = H, (alkyl)amino, alkyl, alkoxy, etc.; Z = e.g., fluorophenylene; Z1 = e.g., 2-oxooxazolidine-3,5-diyl] were prepd. Thus, 1,4-hexahydrothiazepine was N-arylated by 3,4-F2C6H3NO2 and the reduced and N-protected product cyclocondensed with (R)-glycidyl butyrate to give, in 4 addnl. steps, title compd. II. Data for biol. activity of I were given.

IT **216868-64-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(oxooxazolidinylmethyl)thioamides and analogs as bactericides)

RN 216868-64-3 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **216869-05-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-(oxooxazolidinylmethyl)thioamides and analogs as bactericides)
RN 216869-05-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:435073 CAPLUS
DOCUMENT NUMBER: 135:46182
TITLE: Synthesis and use of heterobicyclic substituted phenyl oxazoldinones as antibacterial agents
INVENTOR(S): Paget, Steven; Hlasta, Dennis
PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042242	A1	20010614	WO 2000-US21093	20000802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1206469	A1	20020522	EP 2000-957285	20000802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003516404	T2	20030513	JP 2001-543541	20000802
BR 2000013237	A	20030715	BR 2000-13237	20000802
PRIORITY APPLN. INFO.:			US 1999-148621P P	19990812
			WO 2000-US21093 W	20000802

OTHER SOURCE(S): MARPAT 135:46182
GI

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





AB Compds. I are claimed [wherein: R is OH, O-acyl, OCH2Ph, oxy(hetero)aryl, N3, etc.; X is 0-4 members chosen from halo, OH, SH, NO2, alkoxy, etc.; R5-8 are H, alkyl, CN, NO2, haloalkyl, CHO, etc.; A-D are selected from C, S, O and N to form any 5-10 membered (hetero)arom. ring having 1-4 members selected from the group S, O and N; Z is halo, alkyl, (substituted)(hetero)aryl, CN, CHO, etc.; m is 0-1; and the pyrrolidine ring of the Ph substituent may be a substituted pyrrole]. Forty-nine synthetic examples are provided. For example, the product of the substitution reaction between isoindoline and 3,4-difluoronitrobenzene was reduced to the corresponding amine. The amine was converted to the benzyloxycarbonyl deriv., deprotonated with n-BuLi and treated with (R)-glycidyl butyrate to give the oxazolidinone alc. Conversion of the alc. to amide II proceeded in 3 steps. Compds. of the invention are antibacterial; minimal inhibitory concn. (MIC) were detd. against S. aureus (OC4172), E. faecium (OC3312) and MRSA (OC2878, methicillin resistant Staphylococcus aureus). MIC values ranged from 1 to .gtoreq.128 .mu.g/mL for compds. tested; II had MIC of 2 .mu.g/mL in all strains tested. Treatment/prevention of a condition caused by a bacterial infection is a claimed use of the invention.

IT **344459-84-3P 344459-92-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. and use of heterobicyclic substituted Ph oxazoldinones as antibacterial agents)
RN 344459-84-3 CAPLUS
CN Carbamimidothioic acid, N-cyano-N'-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-92-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **344459-50-3P 344459-52-5P 344459-54-7P**
344459-56-9P 344459-57-0P 344459-59-2P
344459-61-6P 344459-62-7P 344459-63-8P
344459-65-0P 344459-66-1P 344459-67-2P
344459-68-3P 344459-69-4P 344459-70-7P
344459-72-9P 344459-74-1P 344459-76-3P
344459-78-5P 344459-80-9P 344459-82-1P
344459-86-5P 344459-88-7P 344459-90-1P
344459-94-5P 344459-96-7P 344459-97-8P
344459-98-9P 344460-00-0P 344460-01-1P
344460-03-3P 344460-05-5P 344460-07-7P
344460-09-9P 344460-11-3P 344460-13-5P
344460-14-6P 344460-15-7P 344460-17-9P
344460-18-0P 344460-20-4P 344460-22-6P
344460-24-8P 344460-26-0P 344460-28-2P
344460-30-6P 344460-33-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and use of heterobicyclic substituted Ph oxazoldinones as antibacterial agents)
RN 344459-50-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-52-5 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-54-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-56-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-62-7 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-63-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-5-[(pyrazinyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-65-0 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-5-[(pyrazinyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-57-0 CAPLUS
CN Acetamide, N-[[(5R)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-59-2 CAPLUS
CN Acetamide, N-[[(5R)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-61-6 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-66-1 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-67-2 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-68-3 CAPLUS
CN Propanamide, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-69-4 CAPLUS
CN Propanamide, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-70-7 CAPLUS
CN Cyclopropanecarboxamide, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-72-9 CAPLUS

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Cyclopropanecarboxamide, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-74-1 CAPLUS
CN Carbamic acid, [[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-76-3 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344459-78-5 CAPLUS
CN Carbamic acid, [[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-80-9 CAPLUS
CN Methanesulfonamide, N-[[(5R)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-82-1 CAPLUS
CN Methanesulfonamide, N-[[(5R)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 344459-86-5 CAPLUS
CN Carbamimidothioic acid, N-cyano-N'-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-88-7 CAPLUS
CN Guanidine, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 344459-90-1 CAPLUS
CN Guanidine, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-94-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(5-oxido-2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-96-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-01-1 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-03-3 CAPLUS
CN Propanamide, N-[[(5S)-3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-05-5 CAPLUS
CN Cyclopropanecarboxamide, N-[[(5S)-3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 344459-97-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-5-[(3-isothiazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344459-98-9 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl]-5-[(3-isothiazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-00-0 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-07-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-2-methyl-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-09-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-11-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(6H-pyrrolo[3,4-d]pyrimidin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-13-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-2-pyrazinyl-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-14-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(2-pyrazinyl-6H-pyrrolo[3,4-d]pyrimidin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-20-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[5,7-dihydro-2-(3-pyridinyl)-6H-pyrrolo[3,4-d]pyrimidin-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-22-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-24-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2,6-dihydro-2-propylpyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 344460-15-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(3-oxido-2-pyrazinyl-6H-pyrrolo[3,4-d]pyrimidin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-17-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[5,7-dihydro-2-(4-pyridinyl)-6H-pyrrolo[3,4-d]pyrimidin-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-18-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[5,7-dihydro-2-(2-pyridinyl)-6H-pyrrolo[3,4-d]pyrimidin-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.



RN 344460-26-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-28-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-30-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-7-oxo-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-33-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(5,7-dihydro-5-oxo-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **250372-40-8P 250372-93-1P 250373-26-3P**
250373-69-4P 344460-45-3P 344460-46-4P
344460-47-5P 344460-49-7P 344460-51-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and use of heterobicyclic substituted Ph oxazoldinones as antibacterial agents)
RN 250372-40-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 250372-93-1 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250373-26-3 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250373-69-4 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry. Rotation (-).



RN 344460-45-3 CAPLUS
CN 2-Oxazolidinone, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-46-4 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-47-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 344460-49-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344460-51-1 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:680390 CAPLUS
DOCUMENT NUMBER: 133:252421
TITLE: Heteroaromatic ring substituted phenyloxazolidinone antimicrobials
INVENTOR(S): Hutchinson, Douglas K.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: U.S., 27 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6124334	A	20000926	US 1998-223413	19981230

PRIORITY APPLN. INFO.: US 1998-223413 19981230
OTHER SOURCE(S): MARPAT 133:252421
GI



AB Title compds. such as I [Q is a 5-membered heteroarom. having 1-4 N atoms or alternatively a benzannulated 5-membered heteroarom. having 1-4 N atoms; R, R1 = H, MeO, F, Cl; R2 = H, C1-C8 alkyl (optionally substituted with one or more of F, Cl, OH, C1-C8 alkoxy, C1-C8 acyloxy), C3-C6 cycloalkyl, amino, C1-C8 alkylamino, C1-C8 dialkylamino, C1-C8 alkoxy] are prepd.. Thus, I (R = F, R1 = H, R2 = Me, Q = 1H-pyrrol-1-yl) was prepd. in 5 steps starting from 3,4-difluoronitrobenzene and pyrrole. I (R = F, R1 = H, R2 = Me, Q = 1H-pyrrol-1-yl) had min. inhibitory concns. lower than those of vancomycin against Staphylococcus aureus and Streptococcus pneumoniae.

IT **181996-81-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(heteroarom. ring substituted phenyloxazolidinone antimicrobials)

RN 181996-81-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1H-indol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **226220-41-3P 226220-42-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(heteroarom. ring substituted phenyloxazolidinone antimicrobials)

RN 226220-41-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-indol-1-yl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226220-42-4 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(1H-indol-1-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:384192 CAPLUS
DOCUMENT NUMBER: 133:30719
TITLE: Oxazolidinone antibacterial agents having a thiocarbonyl functionality
INVENTOR(S): Hester, Jackson B., Jr.; Nidy, Eldon George; Perricone, Salvatore Charles; Poel, Toni-jo
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032599	A1	20000608	WO 1998-US25308	19981127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9917053	A1	20000619	AU 1999-17053	19981127
AU 764980	B2	20030904		
EP 1133493	A1	20010919	EP 1998-961822	19981127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002531455	T2	20020924	JP 2000-585241	19981127
NZ 511963	A	20031031	NZ 1998-511963	19981127

PRIORITY APPLN. INFO.: WO 1998-US25308 A 19981127
OTHER SOURCE(S): MARPAT 133:30719
GI





AB The title compds. (I) [wherein Z2 = SO2, S(O), S, O, or (un)substituted NH; n = 0-3; R23 and R24 = independently H or F; R1 = H, NH2, NH(alkyl),

L5 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
N(alkyl)2, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, alkyl(thio), alkoxy(carbonyl), CN, or cycloalkyl] were prepd. by various methods, including conversion of the corresponding amides to (alkyl)thioureas or thioamides. Replacement of the O atom with S atom unexpectedly improved the antimicrobial properties of the compds. For example, II was prepd. by treating the corresponding acetamide with Lawesson's Reagent. II inhibited growth of tested gram pos. organisms at concns. 2-4 times lower than the comparison carbonyl-contg. compd.

IT **216868-64-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antibacterial oxazolidinone (alkyl)thioamides or thioureas from the corresponding amides or amines)

RN 216868-64-3 CAPLUS

CN Ethanethioamide, N-[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **216869-05-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of antibacterial oxazolidinone (alkyl)thioamides or thioureas from the corresponding amides or amines)

RN 216869-05-5 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:335397 CAPLUS
DOCUMENT NUMBER: 132:334453
TITLE: Preparation of oxazolidinylmethylthiocarbamic acid derivatives as antibacterial agents
INVENTOR(S): Kado, Noriyuki; Tokuyama, Ryukou; Tsubouchi, Masatoshi; Tomita, Yayoi
PATENT ASSIGNEE(S): Hokuriku Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027830	A1	20000518	WO 1999-JP6260	19991110
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2000204084	A2	20000725	JP 1999-273230	19990927
EP 1130016	A1	20010905	EP 1999-971804	19991110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: JP 1998-320137 A 19981111
JP 1999-273230 A 19990927
WO 1999-JP6260 W 19991110

OTHER SOURCE(S): MARPAT 132:334453
GI



I



II

L5 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB The title compds. I [R1 is optionally substituted alkyl or optionally substituted cycloalkyl; and R2, R3 and R4 are each independently hydrogen, halogeno, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted amino, optionally substituted alkanoyl, optionally substituted cycloalkyloxy contg. a heteroatom as the ring-constituting atom, or an optionally substituted satd. heterocyclic group, or alternatively any two of R2, R3 and R4 together with the benzene ring may form an optionally substituted fused hydrocarbon ring] are prepd. The title compd. II in vitro showed IC50 of 0.39 .mu.g/mL against S. aureus, vs. IC50 of 3.13 .mu.g/mL for linezolid.

IT **172967-25-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of oxazolidinylmethylthiocarbamic acid derivs. as antibacterial agents)

RN 172967-25-8 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:795810 CAPLUS
DOCUMENT NUMBER: 132:35694
TITLE: Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them as antibiotics
INVENTOR(S): Gravestock, Michael Barry
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964417	A2	19991216	WO 1999-GB1753	19990603
WO 9964417	A3	20000203		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2333332	AA	19991216	CA 1999-2333332	19990603
AU 9941571	A1	19991230	AU 1999-41571	19990603
AU 753988	B2	20021031		
BR 9910971	A	20010213	BR 1999-10971	19990603
EP 1082323	A2	20010314	EP 1999-925188	19990603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200000707	A	20020415	EE 2000-707	19990603
JP 2002517498	T2	20020618	JP 2000-553426	19990603
ZA 2000006694	A	20020218	ZA 2000-6694	20001118
BG 105001	A	20010928	BG 2000-105001	20001129
NO 2000006152	A	20010202	NO 2000-6152	20001204
US 6617339	B1	20030909	US 2000-719012	20001205
US 2003144263	A1	20030731	US 2003-340526	20030109

PRIORITY APPLN. INFO.:
GB 1998-12021 A 19980605
GB 1998-20164 A 19980917
GB 1998-26066 A 19981128
WO 1999-GB1753 W 19990603
US 2000-719012 B1 20001205

OTHER SOURCE(S): CASREACT 132:35694; MARPAT 132:35694
GI

L5 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





II

AB Title compds. I and their pharmaceutically-acceptable salts and in-vivo-hydrolyzable esters are described [wherein, for example: X = O or S; Het = (un)substituted C-linked 5-membered heteroaryl ring contg. 2 to 4 heteroatoms independently selected from N, O, and S; Q = (for example) certain substituted phenyls, 2-pyridyls, or 1,2,5,6-tetrahydropyrid-4-yls]. The compds. are useful as antibacterial agents, and have good activity against a broad range of Gram-pos. pathogens, including organisms known to be resistant to most commonly known antibiotics. For instance, 5(R)-[(isoxazol-3-yloxy)methyl]-3-[4-(1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl]oxazolidin-2-one (prepn. given) underwent N-acylation by (R,S)-2,3-O-isopropylideneglyceric acid using EDC and Et3N in CH2Cl2 (39%), followed by deprotection with HCl in aq. THF (80%), to give title compd. II. Against coagulase-neg. staphylococci, II had an MIC (.mu.g/mL) of 0.13 for methicillin-sensitive strains, and 0.50 for methicillin-resistant strains.

IT **252280-03-8P 252328-65-7P 252328-66-8P 252328-70-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of antibiotic oxazolidinone derivs.)

RN 252280-03-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 252328-65-7 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1S,4S)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]phenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252328-66-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-fluorophenyl]-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 252328-70-4 CAPLUS

L5 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 8-Azabicyclo[3.2.1]oct-2-ene, 8-[(acetyloxy)acetyl]-3-[2-fluoro-4-[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **252328-67-9P 252328-68-0P 252328-69-1P 252328-71-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antibiotic oxazolidinone derivs.)

RN 252328-67-9 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[(acetyloxy)acetyl]-5-[2-fluoro-4-[(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-3-oxazolidinyl]phenyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252328-68-0 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[2-fluoro-4-[(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-3-oxazolidinyl]phenyl]-5-(hydroxyacetyl)-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 252328-69-1 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[(2S)-2,3-dihydroxy-1-oxopropyl]-5-[2-fluoro-4-[(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-3-oxazolidinyl]phenyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252328-71-5 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-[2-fluoro-4-[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl]phenyl]-8-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 252342-36-2 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-[2-fluoro-4-[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **172967-24-7P 252342-35-1P 252342-36-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of antibiotic oxazolidinone derivs.)
RN 172967-24-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252342-35-1 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-5-[2-fluoro-4-[(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-3-oxazolidinyl]phenyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



~~L5~~ ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:747431 CAPLUS
DOCUMENT NUMBER: 131:351320
TITLE: Preparation of oxazolidinylmethyldithiocarbamic acid derivatives as bactericides and fungicides
INVENTOR(S): Yoshida, Toshihiko; Tokuyama, Tatsuteru; Tomita, Yayoi
PATENT ASSIGNEE(S): Hokuriku Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 90 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11322729	A2	19991124	JP 1999-57378	19990304
PRIORITY APPLN. INFO.:			JP 1998-74982	19980309

OTHER SOURCE(S): MARPAT 131:351320
GI



AB Title compds. I [R = Ph, substituted Ph; R1 = alkyl, cycloalkyl, aryl, aralkyl, etc.) and their salts, useful as bactericides and fungicides, are prepd. Thus, reaction of (S)-5-aminomethyl-2-oxo-3-[4-(thiomorpholin-4-yl)phenyl]oxazolidine with CS2 in CH2Cl2 in the presence of Et3N gave, after treatment with MeI, Me (S)-N-[2-oxo-3-[4-(thiomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyldithiocarbamate. Me (S)-N-[2-oxo-3-[3-fluoro-4-(thiomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyldithiocarbamate showed bactericidal activity superior to that of linezolid.
IT **250374-27-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolidinylmethyldithiocarbamic acid derivs. as bactericides and fungicides)
RN 250374-27-7 CAPLUS
CN Carbamodithioic acid, [[(5S)-3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **250372-40-8P 250372-93-1P 250373-26-3P**
250373-69-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of oxazolidinylmethyldithiocarbamic acid derivs. as bactericides and fungicides)

RN 250372-40-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250372-93-1 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 250373-26-3 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250373-69-4 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1,3-dihydro-2H-isoindol-2-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:584814 CAPLUS
DOCUMENT NUMBER: 131:214279
TITLE: Preparation of bicyclylaryloxazolidinones as antibacterials
INVENTOR(S): Barbachyn, Michael R.; Thomas, Richard C.; Cleek, Gary L.; Thomasco, Lisa M.; Gadwood, Robert C.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 339,979, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5952324	A	19990914	US 1997-51466	19970514
WO 9615130	A1	19960523	WO 1995-US12751	19951031
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1994-339979 B2 19941115
WO 1995-US12751 W 19951031
OTHER SOURCE(S): MARPAT 131:214279
GI



AB Title compds. [I; X = O, S, SO, SO2; X1 = (CH2)a ; X2 = (CH2)b; X3 = (CH2)c; X4 = (CH2)d; X5 = (CH2)e; a = 0-3; b-e = 0-2; R1 = H, F, Cl, OMe; R2 = H, (substituted) alkyl; with provisos], were prepd. I are effective against gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. Thus, (S)-N-[[3-[3-fluoro-4-(tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide in acetone/H2O was stirred with N-methylmorpholine N-oxide and OsO4 for 18 h to give (S)-N-[[3-[3-fluoro-4-(tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide S,S-dioxide. The latter showed ED50 = 3.5 mg/kg orally against Staphylococcus aureus UC9213 in mice.

L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

IT **179339-60-7P 179339-65-2P 179339-66-3P**
179339-75-4P 179339-76-5P 179339-77-6P
179339-78-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bicyclylaryloxazolidinones as antibacterials)

RN 179339-60-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylphenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-65-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1S,4S)-2-thia-5-azabicyclo[2.2.1]hept-5-ylphenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-66-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1S,4S)-2,2-dioxido-2-thia-5-azabicyclo[2.2.1]hept-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 179339-75-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-76-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-2-oxido-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-77-6 CAPLUS

L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 179339-58-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylphenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-59-4 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylphenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-63-0 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1S,4S)-2-thia-5-azabicyclo[2.2.1]hept-5-ylphenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(3aS,6aR)-tetrahydro-2,2-dioxido-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-78-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **179339-56-1P 179339-58-3P 179339-59-4P**
179339-63-0P 179339-64-1P 179339-73-2P
179339-74-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of bicyclylaryloxazolidinones as antibacterials)
RN 179339-56-1 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylphenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 179339-64-1 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1S,4S)-2-thia-5-azabicyclo[2.2.1]hept-5-ylphenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-73-2 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-74-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:468057 CAPLUS
DOCUMENT NUMBER: 131:116227
TITLE: Preparation of 3-Phenyl-5-(acylaminomethyl)oxazolidinone derivatives antibacterial agents
INVENTOR(S): Yoon, Yeo Hong; Kim, Hak Sung; Lee, Kwang Ho; Lee, Kwang Hyuk; Kang, Jin Ah; Lee, Youn Ha
PATENT ASSIGNEE(S): Cheil Jedang Corp., S. Korea
SOURCE: U.S., 15 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5929083	A	19990727	US 1997-891835	19970714
PRIORITY APPLN. INFO.:			KR 1997-20523	19970524
OTHER SOURCE(S):		MARPAT 131:116227		

GI



I



II

AB Antibacterially effective compds. of formula [I; R1, R4, R5 = hydrogen, (un)substituted C1-6 alkyl, C3-6 cycloalkyl; R2 = H, F, Cl, methoxy; R3 = hydrogen, (un)substituted C1-6 alkyl, C3-6 cycloalkyl, amino, C1-6 alkylamino, C1-6 dialkylamino, C1-6 alkoxy; X, together with the carbon to which X is attached, form (i) carbonyl, (ii) thiocarbonyl, (iii) ethyleneketal, propyleneketal, dimethylketal or diethylketal, (iv) oxime unsubstituted or substituted with (un)substituted C1-5 alkyl or acyl, (v) hydrazone unsubstituted or substituted with (un)substituted C1-5 alkyl, C1-5 acyl, or C1-5 alkoxycarbonyl or C1 -C5 alkylsulfonyl (vi) imine unsubstituted or substituted with (un)substituted C1-5 alkyl or C1 -C5 acyl, or (vii) carbon-carbon double bond unsubstituted or substituted with C1-4 alkoxycarbonyl, or C1-4 alkyl which is optionally substituted with Cl, F, hydroxy, C1 -C3 alkoxy or phenyl]. These compds. are remarkably effective antibacterial agents compared to the well-known antibiotic vancomycin. Thus, (S)-N-[3-fluoro-4-(6-oxo-3-azabicyclo[3.1.1]heptan-3-yl)phenyl]-[(2- oxo-5-oxazolidinyl)methyl]acetamide (prepn. given) was oximated by hydroxylamine hydrochloride in the presence of NaHCO3 in 95% ethanol under reflux for 6 h to give the title compd. (II). II showed min. inhibitory concn. of 1.00, 1.00, 0.50, 0.50, 0.50, 0.50, and 0.25 .mu.g/mL against Staphylococcus aureus ATCC 29213, MRSA (methicillin-resistant Staphylococcus aureus) C6068 C, Staphylococcus epidermidis ATCC 12228, Enterococcus faecium C 2252 E, Enterococcus faecalis ATCC 29212, and Streptococcus pyogenes ATCC 8668, resp., vs. 1.00, 1.00, 1.00, 4.00, 2.00, and 0.50, resp., for vancomycin.

IT **232283-94-2P 232283-95-3P 232283-96-4P**
232283-97-5P 232283-98-6P 232283-99-7P
232284-00-3P 232284-01-4P 232284-02-5P
232284-03-6P 232284-04-7P 232284-05-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenyl(acylaminomethyl)oxazolidinone derivs. as antibacterial agents)

RN 232283-94-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(7-methylspiro[3-azabicyclo[3.1.1]heptane-6,2'-[1,3]dioxolan]-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 232283-95-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(6-methyl-7-oxo-3-azabicyclo[3.1.1]hept-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232283-96-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(hydroxyimino)-7-methyl-3-

L5 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
azabicyclo[3.1.1]hept-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232283-97-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(methoxyimino)-7-methyl-3-azabicyclo[3.1.1]hept-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232283-98-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(spiro[3-azabicyclo[3.1.1]heptane-6,2'-[1,3]dioxolan]-3-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232283-99-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(6-oxo-3-azabicyclo[3.1.1]hept-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.



RN 232284-00-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(hydroxyimino)-3-azabicyclo[3.1.1]hept-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232284-01-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(methoxyimino)-3-azabicyclo[3.1.1]hept-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232284-02-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1R,5S)-1-methylspiro[3-azabicyclo[3.1.1]heptane-6,2'-[1,3]dioxolan]-3-yl]phenyl]-2-oxo-5-

L5 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 232284-05-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1R,5S)-6-(methoxyimino)-1-methyl-3-azabicyclo[3.1.1]hept-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT **232284-11-6P 232284-12-7P 232284-13-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenyl(acylaminomethyl)oxazolidinone derivs. as antibacterial agents)
RN 232284-11-6 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(7-methylspiro[3-azabicyclo[3.1.1]heptane-6,2'-[1,3]dioxolan]-3-yl)phenyl]-5-(hydroxymethyl)-, stereoisomer (9CI) (CA INDEX NAME)



RN 232284-12-7 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(7-methylspiro[3-azabicyclo[3.1.1]heptane-

L5 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232284-03-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1R,5S)-1-methyl-6-oxo-3-azabicyclo[3.1.1]hept-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232284-04-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1R,5S)-6-(hydroxyimino)-1-methyl-3-azabicyclo[3.1.1]hept-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L5 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
6,2'-[1,3]dioxolan]-3-yl)phenyl]-5-[[(methylsulfonyl)oxy]methyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 232284-13-8 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(7-methylspiro[3-azabicyclo[3.1.1]heptane-6,2'-[1,3]dioxolan]-3-yl)phenyl]-, stereoisomer (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:370027 CAPLUS
DOCUMENT NUMBER: 131:18998
TITLE: Heteroaromatic ring substituted phenyloxazolidinone antimicrobials
INVENTOR(S): Hutchinson, Douglas K.
PATENT ASSIGNEE(S): Pharmacia & Upjohn, USA
SOURCE: U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 384,278, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5910504	A	19990608	US 1997-875800	19970804
WO 9623788	A1	19960808	WO 1996-US718	19960129

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD

PRIORITY APPLN. INFO.: US 1995-384278 B2 19950203
WO 1996-US718 W 19960129
OTHER SOURCE(S): MARPAT 131:18998
GI



I

AB Title compds. I [Q = (un)substituted N-heterocyclyl; R, R1 = H, OMe, F, Cl; R2 = H, (un)substituted alkyl, cycloalkyl, amino, alkylamino, dialkylamino, alkoxy] were prepd. and tested for antibacterial activity. Thus, I (Q = 1H-pyrrol-1-yl, R = H, R1 = F, R2 = Me) was prepd. starting from pyrrole and 3,4-F2C6H3NO2 and proceeding via 3-fluoro-1-nitro-4-(1H-pyrrol-1-yl)benzene, 3-fluoro-1-(phenylmethoxycarbonylamino)-4-(1H-pyrrol-1-yl)benzene, (S)-[3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methanol, and (S)-[3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl azide. I (Q = 1H-pyrrol-1-yl, R = H, R1 = F, R2 = Me) showed a min. inhibitory concn. of <0.5 .mu.g/mL in in vitro tests against Staphylococcus aureus and Streptococcus pneumoniae.
IT **181996-81-6P**

L5 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
([(acylamino)methyl](heterocyclylphenyl)oxazolidinone antibacterial agents)
RN 181996-81-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1H-indol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **226220-41-3P 226220-42-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
([(acylamino)methyl](heterocyclylphenyl)oxazolidinone antibacterial agents)
RN 226220-41-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-indol-1-yl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226220-42-4 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(1H-indol-1-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:325931 CAPLUS
DOCUMENT NUMBER: 130:338127
TITLE: Preparation of N-oxodiazepinophenyloxazolidinones as bactericides
INVENTOR(S): Hester, Jackson B., Jr.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924428	A1	19990520	WO 1998-US22639	19981030

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2303959	AA	19990520	CA 1998-2303959	19981030
AU 9912778	A1	19990531	AU 1999-12778	19981030
AU 739055	B2	20011004		
US 5998406	A	19991207	US 1998-183432	19981030
EP 1030852	A1	20000830	EP 1998-956200	19981030
EP 1030852	B1	20030917		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 9813985	A	20000926	BR 1998-13985	19981030
JP 2001522849	T2	20011120	JP 2000-520440	19981030
NZ 504503	A	20021025	NZ 1998-504503	19981030
AT 250054	E	20031015	AT 1998-956200	19981030
RU 2215740	C2	20031110	RU 2000-114891	19981030
NO 2000002434	A	20000511	NO 2000-2434	20000511

PRIORITY APPLN. INFO.: US 1997-65376P P 19971112
WO 1998-US22639 W 19981030
OTHER SOURCE(S): MARPAT 130:338127
GI



I

AB Title compds. [I; R1 = RZ1Z2; R = H, (un)substituted alkyl, alkenyl, alkynyl; R2 = CH2NHZR3; R3 = NH2, alkyl, alkoxy, etc.; ZGO or CS; Z1 = 5-oxo-1,2,3,4,6,7-hexahydro-1,4-diazepine-4,1-diyl; Z2 = (un)substituted 1,4-phenylene] were prepd. Thus, I [R1 = 3-fluoro-4-(5-oxo-1,2,3,4,6,7-hexahydro-1,4-diazepine-1-yl)phenyl, R2 = CH2NHAc] was prepd. Data for biol. activity of I were given.

L5 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
IT **172967-24-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-oxodiazepinophenyloxazolidinones as bactericides)
RN 172967-24-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **172966-59-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-oxodiazepinophenyloxazolidinones as bactericides)
RN 172966-59-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:166612 CAPLUS
DOCUMENT NUMBER: 130:209696
TITLE: Antibiotic oxazolidinone derivatives
INVENTOR(S): Gravestock, Michael Barry
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9910342	A1	19990304	WO 1998-GB2476	19980818
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1005468	A1	20000607	EP 1998-938836	19980818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001514178	T2	20010911	JP 2000-507671	19980818
US 6605630	B1	20030812	US 2000-486092	20000218
US 2003216374	A1	20031120	US 2003-414320	20030415

PRIORITY APPLN. INFO.: GB 1997-17807 A 19970822
WO 1998-GB2476 W 19980818
US 2000-486092 A3 20000218
OTHER SOURCE(S): MARPAT 130:209696
GI



I



Q1 Q2 Q3

AB The title compds. I [T = Q1, Q2, Q3; R1 = NHC(O)Rb with Rb = (1-4C)alkyl; R2, R3 = H, F; >A-B- is >C:CH- (but not when T is Q1) or >CH-CH2-; R5 = H, R10CO, R10SO2, R10CS with R10 = optionally substituted Ph, (1-10C)alkyl; R5 and R6 are linked to give a 5- or 6-membered ring which is fused to the ring shown in Q1, Q2, Q3 so as to give an optionally substituted bicyclic ring], antibacterial agents, were prepd. E.g., N-((5S)-3-(4-((7aS)[3H,5H]-

L5 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
3-oxo-1,7a-dihydropyrrolo[1,2-c]oxazol-6-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide was prepd. I are effective against gram-pos. pathogens.
IT **220992-80-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of antibacterial oxazolidinone derivs.)
RN 220992-80-3 CAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[4-(1,5,8,8a-tetrahydro-3-oxo-3H-oxazolo[3,4-a]pyridin-7-yl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **220992-73-4P 220992-74-5P 220992-76-7P**
220992-81-4P 220993-07-7P 220993-08-8P
220993-10-2P 220993-11-3P 220993-12-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antibacterial oxazolidinone derivs.)
RN 220992-73-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,3,4,6,9,9a-hexahydro-1,4-dioxopyrido[2,1-c][1,4]oxazin-8-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220992-74-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,2,3,5,8,8a-hexahydro-1,3-dioxo-2-phenylimidazo[1,5-a]pyridin-7-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-

L5 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220992-76-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2-ethyl-1,2,3,5,8,8a-hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-7-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220992-81-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(hexahydro-3-oxo-3H-oxazolo[3,4-a]pyridin-7-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220993-07-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(7aS)-5,7a-dihydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 220993-08-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(7aS)-5,7a-dihydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220993-10-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(7aS)-5,7a-dihydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:794995 CAPLUS
DOCUMENT NUMBER: 130:38373
TITLE: Preparation of thiocarbonyloxazolidinones as antibacterial agents
INVENTOR(S): Hester, Jackson B., Jr.; Nidy, Eldon George; Perricone, Salvatore Charles; Poel, Toni-jo
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA; Hester, Jackson B., Jr.
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9854161	A1	19981203	WO 1998-US9889	19980518
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9874883	A1	19981230	AU 1998-74883	19980513
AU 737995	B2	20010906		
EP 984947	A1	20000315	EP 1998-922303	19980518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9815518	A	20001121	BR 1998-15518	19980518
NZ 501412	A	20011130	NZ 1998-501412	19980518
JP 2002501530	T2	20020115	JP 1999-500722	19980518
RU 2208613	C2	20030720	RU 1999-128083	19980518
NO 9905846	A	20000128	NO 1999-5846	19991129
FI 9902555	A	19991130	FI 1999-2555	19991130
MX 9911069	A	20000430	MX 1999-11069	19991130

PRIORITY APPLN. INFO.: US 1997-48342P P 19970530
WO 1998-US9889 W 19980518

OTHER SOURCE(S): MARPAT 130:38373
GI



I



II

L5 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 220993-11-3 CAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[4-[(7aS)-2,3,5,7a-tetrahydro-3-oxo-1H-pyrrolo[1,2-c]imidazol-6-yl]phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220993-12-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(7aR)-5,7a-dihydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB Chiral title compds. AGCH2NHCSR [A is (un)substituted Ph, indolinyl; G is 2-oxo-5-oxazolidinyl; R is H, NH2, alkyl, cycloalkyl, etc.] or pharmaceutical acceptable salts are prepd., from amines with Lawesson's Reagent or 1,1'-thiocarbonyldi-2(1H)-pyridone, as antibacterial agents. Title compds. I and II were tested in vitro by std. agar diln. method.

IT **216869-05-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of thiocarbonyloxazolidinones as antibacterial agents)

RN 216869-05-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **216868-64-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of thiocarbonyloxazolidinones as antibacterial agents)

RN 216868-64-3 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:324112 CAPLUS
DOCUMENT NUMBER: 126:293348
TITLE: Preparation of 5-acylaminomethyl-3-(N-oxidoheterocyclyl)phenyl-2-oxazolidinones as antibacterial prodrugs
INVENTOR(S): Gadwood, Robert C.; Kamdar, Bharat V.
PATENT ASSIGNEE(S): Upjohn Co., USA; Gadwood, Robert C.; Kamdar, Bharat V.
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9710223	A1	19970320	WO 1996-US14135	19960909
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
AU 9669640	A1	19970401	AU 1996-69640	19960909
JP 11512429	T2	19991026	JP 1996-511993	19960909
EP 1019385	A1	20000719	EP 1996-930676	19960909
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
US 6277985	B1	20010821	US 1996-709998	19960909
US 2001051722	A1	20011213	US 2001-894019	20010628
US 6512112	B2	20030128		
US 2002107402	A1	20020808	US 2001-988078	20010628
US 6441188	B2	20020827		
US 2002120152	A1	20020829	US 2001-988079	20010628
US 6515135	B2	20030204		
US 2002177707	A1	20021128	US 2001-988076	20010628
US 6525193	B2	20030225		
US 6518427	B1	20030211	US 2001-988077	20010628

PRIORITY APPLN. INFO.: US 1995-3838P P 19950915
US 1996-709998 A3 19960909
WO 1996-US14135 W 19960909
OTHER SOURCE(S): MARPAT 126:293348
GI



I

L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB Title compds. [I; R = N-attached-N-oxido-hetero(bi)cyclyl; R1 = CHO, Ac, CO2Me, etc.; R2,R3 = H, F, Cl] were prepd. Thus, I (R = 4-hydroxyacetyl-1-piperazinyl, R1 = Ac, R2 = F, R3 = H) was oxidized to give I (R = 4-hydroxyacetyl-1-oxido-1-piperazinyl, R1 = Ac, R2 = F, R3 = H). Data for biol. activity of I were given.

IT **189038-44-6P 189038-50-4P 189038-53-7P**
189157-56-0P 189157-59-3P 189157-60-6P
189157-61-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5-acylaminomethyl-3-(N-oxidoheterocyclyl)phenyl-2-oxazolidinones as antibacterial prodrugs)

RN 189038-44-6 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(2,2,5-trioxido-2-thia-5-azabicyclo[2.2.1]hept-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [1S,4S,5(S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189038-50-4 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(5-oxido-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [1S,4S,5(S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189038-53-7 CAPLUS

L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[3-[3-fluoro-4-(8-oxido-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189157-56-0 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[2-(hydroxymethyl)-8-oxido-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189157-59-3 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[hexahydro-5-(hydroxyacetyl)-2-oxidopyrrolo[3,4-c]pyrrol-2(1H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [2(S),3aR,6aS]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189157-60-6 CAPLUS
CN Acetamide, N-[[3-[4-[5-(cyclopropylcarbonyl)hexahydro-2-oxidopyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, [2(S),3aR,6aS]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 189157-61-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[hexahydro-5-(methylsulfonyl)-2-oxidopyrrolo[3,4-c]pyrrol-2(1H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [2(S),3aR,6aS]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:14895 CAPLUS
DOCUMENT NUMBER: 126:47210
TITLE: Preparation of spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones as antimicrobial agents
INVENTOR(S): Barbachyn, Michael Robert; Brickner, Steven J.; Hutchinson, Douglas K.
PATENT ASSIGNEE(S): Upjohn Co., USA; Barbachyn, Michael Robert; Brickner, Steven J.; Hutchinson, Douglas K.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9635691	A1	19961114	WO 1996-US5202	19960418
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR				
CA 2218088	AA	19961114	CA 1996-2218088	19960418
AU 9654849	A1	19961129	AU 1996-54849	19960418
AU 702752	B2	19990304		
EP 828741	A1	19980318	EP 1996-911768	19960418
EP 828741	B1	20010829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1184481	A	19980610	CN 1996-193861	19960418
CN 1068328	B	20010711		
JP 11506430	T2	19990608	JP 1996-534070	19960418
NZ 306310	A	20010525	NZ 1996-306310	19960418
AT 204874	E	20010915	AT 1996-911768	19960418
ES 2162047	T3	20011216	ES 1996-911768	19960418
PT 828741	T	20020228	PT 1996-96911768	19960418
US 6090820	A	20000718	US 1997-202195	19971107
FI 9704180	A	19971110	FI 1997-4180	19971110
NO 9705158	A	19980109	NO 1997-5158	19971110
HK 1009449	A1	20020628	HK 1998-110441	19980904
CN 1336375	A	20020220	CN 2000-132826	20001031

PRIORITY APPLN. INFO.: US 1995-438705 A2 19950511
WO 1996-US5202 W 19960418
OTHER SOURCE(S): MARPAT 126:47210
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I and II; R1 = (un)substituted NH, CH2; R2 = H, Me; R3 = H, F, Cl, MeO; R4 = H, C1-8 alkyl, C3-6 cycloalkyl, etc.; m = 0-2; n = 1-3; o = 0-3; p = 1-3], useful for treating microbial infections in humans or other warm-blooded animals, were prepd. Thus, treatment of cis-3-(carbobenzyloxy)-7-{4-[(carbobenzyloxy)amino]-2-fluorophenyl}-3,7-diazabicyclo[3.3.0]octane with BuLi in THF followed by addn. of (R)-(-)-glycidyl butyrate, reaction of the intermediate (R)-cis-III with MeSO3H in the presence of TEA in CH2Cl2, reaction of the corresponding methanesulfonate with concd. NH4OH in THF/iPrOH and alkylation of the amine (S)-cis-IV with Ac2O in the presence of pyridine in CH2Cl2 afforded (S)-cis-I [R1 = Cbz-substituted N; R2 = H; R3 = 3-F; R4 = Me; m = n = o = 1] which showed MIC of 4 and 2 .mu.M/mL against Staphylococcus aureus UC 9213 and Streptococcus pneumoniae UC 9912, resp.

IT **184902-97-4P 184902-99-6P 184903-15-9P 184903-19-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones as antimicrobial agents)

RN 184902-97-4 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, 5-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]hexahydro-, phenylmethyl ester, [5(S)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184902-99-6 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(hexahydro-5-[(phenylmethoxy)acetyl]pyrrolo[3,4-c]pyrrol-2(1H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [2(S)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-15-9 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine-1-carboxylic acid, 6-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]octahydro-, phenylmethyl ester, [4aR-[4a.alpha.,6(S*),7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-19-3 CAPLUS
CN Acetamide, N-[[3-[4-[1-[(acetyloxy)acetyl]octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, [4aR-[4a.alpha.,6(S*),7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **184903-01-3P 184903-03-5P 184903-05-7P 184903-07-9P 184903-09-1P 184903-11-5P 184903-13-7P 184903-17-1P 184903-21-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones as antimicrobial agents)

RN 184903-01-3 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[hexahydro-5-(hydroxyacetyl)pyrrolo[3,4-c]pyrrol-2(1H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [2(S)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-03-5 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[5-[(4,5-dihydro-5-isoxazolyl)carbonyl]hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [2(S)-cis]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-05-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[hexahydro-5-(1H-indol-2-ylcarbonyl)pyrrolo[3,4-c]pyrrol-2(1H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [2(S)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184903-07-9 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, 5-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]hexahydro-, methyl ester, [5(S)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-09-1 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(5-formylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [2(S)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-11-5 CAPLUS

L5 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184903-21-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[octahydro-1-(hydroxyacetyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [4aR-[4a.alpha.,6(S*),7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **184903-25-1P 184903-26-2P 184903-27-3P**
184903-31-9P 184903-35-3P 184903-37-5P
184903-41-1P 184903-43-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones as antimicrobial agents)

RN 184903-25-1 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, 5-[2-fluoro-4-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]hexahydro-, phenylmethyl ester, [5(R)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-[[3-[4-(5-acetylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-13-7 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, 5-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]hexahydro-, phenylmethyl ester, [5(S)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-17-1 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine-1-carboxylic acid, 6-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]octahydro-, methyl ester, [4aR-[4a.alpha.,6(S*),7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184903-26-2 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, 5-[4-[5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]hexahydro-, phenylmethyl ester, [5(S)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-27-3 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [2(S)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-31-9 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-[4-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-, phenylmethyl ester, [5(R)-cis]- (9CI) (CA INDEX NAME)

L5 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.



RN 184903-35-3 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine-1-carboxylic acid, 6-[2-fluoro-4-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]octahydro-, phenylmethyl ester, [4aR-[4a.alpha.,6(R*),7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-37-5 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine-1-carboxylic acid, 6-[2-fluoro-4-[5-[[[(3-nitrophenyl)sulfonyl]oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]octahydro-, phenylmethyl ester, [4aR-[4a.alpha.,6(R*),7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L5 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184903-41-1 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine-1-carboxylic acid, 6-[4-[5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]octahydro-, phenylmethyl ester, [4aR-[4a.alpha.,6(S*),7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184903-43-3 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [4aR-[4a.alpha.,6(S*),7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:659781 CAPLUS
DOCUMENT NUMBER: 125:300987
TITLE: Substituted aryl- and heteroarylphenyloxazolidinones
INVENTOR(S): Barbachyn, Michael R.; Brickner, Steven J.
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 831,213, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5565571	A	19961015	US 1994-233903	19940428
AT 146783	E	19970115	AT 1992-921324	19921005
JP 3176626	B2	20010618	JP 1993-508405	19921005
US 5654428	A	19970805	US 1995-466956	19950606
US 5654435	A	19970805	US 1995-470522	19950606
US 5756732	A	19980526	US 1995-466958	19950606
US 5801246	A	19980901	US 1995-466955	19950606
US 5929248	A	19990727	US 1997-842282	19970423

PRIORITY APPLN. INFO.: US 1991-786107 B2 19911101
US 1992-831213 B2 19920207
WO 1992-US8267 A1 19921005
US 1994-233903 A3 19940428
US 1995-466955 A3 19950606
OTHER SOURCE(S): MARPAT 125:300987
GI



I

AB Title compds. I [R = substituted Ph; R1 = H, (un)substituted alkyl, cycloalkyl, alkenyl, Ph, furyl, thienyl, pyrrolidinyl, pyridyl, alkoxy, amino, CH2OH, alkoxymethyl, acyl] were prepd. for use as bactericides and tuberculostatics (no data). Thus, I [R = 4-(3-pyridyl)-3,5-difluorophenyl, R1 = me] was obtained from 3,5-F2C6H3NH2, 3-bromopyridine and CH2:CHCH2Br in 8 steps.
IT **183124-48-3P 183124-73-4P 183124-74-5P 183124-76-7P 183124-96-1P 183124-98-3P 183125-00-0P 183125-02-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryl- and arylphenyloxazolidinones as bactericides and tuberculostatics)
RN 183124-48-3 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(6-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 183124-73-4 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(3-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-74-5 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(4-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-76-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 183125-02-2 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 183124-96-1 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(3-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-98-3 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(4-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183125-00-0 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(6-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:618741 CAPLUS
DOCUMENT NUMBER: 125:247827
TITLE: Preparation of N-(heteroarylphenyl)oxazolidin-2-ones as bactericides
INVENTOR(S): Hutchinson, Douglas K.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9623788	A1	19960808	WO 1996-US718	19960129
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD				
CA 2208603	AA	19960808	CA 1996-2208603	19960129
AU 9648998	A1	19960821	AU 1996-48998	19960129
AU 703465	B2	19990325		
BR 9607017	A	19971028	BR 1996-7017	19960129
EP 807112	A1	19971119	EP 1996-905168	19960129
EP 807112	B1	20010905		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
CN 1172484	A	19980204	CN 1996-191740	19960129
CN 1075073	B	20011121		
JP 10513446	T2	19981222	JP 1996-523572	19960129
RU 2154645	C2	20000820	RU 1997-114833	19960129
AT 205205	E	20010915	AT 1996-905168	19960129
ES 2163004	T3	20020116	ES 1996-905168	19960129
NO 9703550	A	19971003	NO 1997-3550	19970801
MX 9705881	A	20000331	MX 1997-5881	19970801
FI 9703217	A	19970804	FI 1997-3217	19970804
US 5910504	A	19990608	US 1997-875800	19970804
HK 1008898	A1	20020906	HK 1998-109662	19980804

PRIORITY APPLN. INFO.: US 1995-384278 A2 19950203
WO 1996-US718 W 19960129
OTHER SOURCE(S): MARPAT 125:247827
GI



AB Title compds. [I; R = (un)substituted (benz- or pyridoanellated) pyrrolo,

L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
imidazo, triazolo, etc.; R1 = H, F, Cl, OMe; R2 = H, NH2, alkyl, alkoxy, etc] were prepd. Thus, 3,4-F2C6H3NO2 was condensed with pyrrole and the reduced product amidated by ClCO2CH2Ph to give 4-RC6H4NHCO2CH2Ph (R = pyrrolo) which was cyclocondensed with (R)-glycidyl butyrate and the product converted in 3 steps to I (R = pyrrolo, R1 = H, R2 = Me). The latter had MIC of <0.5.mu.g/mL against Streptococcus pneumoniae UC 9912 and Staphylococcus aureus UC 9213.

IT **181996-81-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(heteroarylphenyl)oxazolidin-2-ones as bactericides)

RN 181996-81-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1H-indol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **181997-19-3P 181997-20-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-(heteroarylphenyl)oxazolidin-2-ones as bactericides)

RN 181997-19-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-indol-1-yl)phenyl]-5-(hydroxymethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 181997-20-6 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(1H-indol-1-yl)phenyl]-, (S)- (9CI) (CA INDEX NAME)

L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



L5 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1996:476651 CAPLUS
DOCUMENT NUMBER:	125:142706
TITLE:	Phenyloxazolidinone antimicrobials
INVENTOR(S):	Hutchinson, Douglas K.; Barbachyn, Michael R.; Taniguchi, Mikio; Munesada, Kiyotaka; Yamada, Hiroyoshi; Brickner, Steven J.
PATENT ASSIGNEE(S):	Upjohn Co., USA
SOURCE:	PCT Int. Appl., 88 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613502	A1	19960509	WO 1995-US10992	19950912
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2200433	AA	19960509	CA 1995-2200433	19950912
AU 9536254	A1	19960523	AU 1995-36254	19950912
AU 694271	B2	19980716		
EP 788498	A1	19970813	EP 1995-933718	19950912
EP 788498	B1	20010816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1162312	A	19971015	CN 1995-195908	19950912
CN 1068325	B	20010711		
HU 77602	A2	19980629	HU 1997-2015	19950912
BR 9509136	A	19980721	BR 1995-9136	19950912
JP 10508017	T2	19980804	JP 1995-514540	19950912
RU 2134692	C1	19990820	RU 1997-108157	19950912
AT 204277	E	20010915	AT 1995-933718	19950912
ES 2162941	T3	20020116	ES 1995-933718	19950912
PT 788498	T	20020228	PT 1995-95933718	19950912
PL 183512	B1	20020628	PL 1995-319873	19950912
SK 282869	B6	20030109	SK 1997-494	19950912
CZ 291847	B6	20030618	CZ 1997-1217	19950912
US 5883093	A	19990316	US 1997-913190	19970423
FI 9701774	A	19970425	FI 1997-1774	19970425
NO 9701946	A	19970625	NO 1997-1946	19970425
PRIORITY APPLN. INFO.:			US 1994-329717 A2	19941026
			WO 1995-US10992 W	19950912

OTHER SOURCE(S): MARPAT 125:142706
GI

L5 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II III

AB Title compds. I [Q = certain substituted 1-azetidinyl and 1-pyrrolidinyl substituents; R1 = H, OMe, F, Cl; R2 = H, (un)substituted alkyl, cycloalkyl, (di)(alkyl)amino, alkoxy] and their pharmaceutically acceptable salts are claimed. The compds. are useful antimicrobial agents, effective against a no. of human and veterinary pathogens, particularly aerobic gram-pos. bacteria, including multiply-resistant staphylococci, enterococci and streptococci, as well as anaerobic organisms such as bacteroids and clostridia species, and acid-fast bacteria such as Mycobacterium tuberculosis and other mycobacterial species. For example, 1-(diphenylmethyl)-3-azetidinol·HCl underwent N-deprotection and N-arylation with 3,4-difluoronitrobenzene (65%), O-silylation with tert-BuSiMe2Cl (74%), hydrogenation of the nitro group to an amine and N-benzyloxycarbonylation (43%), and lithiation and reaction with (R)-glycidyl butyrate (75%), to give intermediate oxazolidinylmethanol deriv. II. This was subjected to O-mesylation and conversion to an azide (56%), hydrogenolysis of the azide and acetylation of the resulting amine (84%), desilylation, and oxidn. of the deprotected alc. (47%), to give title compd. III. The MIC values of III against Staphylococcus aureus UC 9213 and Streptococcus pneumoniae UC 9912 were 1 and 0.5 .mu.g/mL, resp.

IT **179620-72-5P 179620-82-7P 179620-83-8P**
179620-84-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; phenyloxazolidinone antimicrobials)

RN 179620-72-5 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(tetrahydro-2,2-dimethyl-4H-1,3-dioxolo[4,5-b]pyrrol-4-yl)phenyl]-5-(hydroxymethyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 179620-82-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,4-dioxa-7-azaspiro[4.4]non-7-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179620-83-8 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(1,4-dioxa-7-azaspiro[4.4]non-7-yl)-3-fluorophenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179620-84-9 CAPLUS
CN Acetamide, N-[[3-[4-(1,4-dioxa-7-azaspiro[4.4]non-7-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **179620-32-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenyloxazolidinone antimicrobials)
RN 179620-32-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(tetrahydro-2,2-dimethyl-4H-1,3-dioxolo[4,5-b]pyrrol-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:467068 CAPLUS
DOCUMENT NUMBER: 125:142710
TITLE: Preparation of [(azabicyclyl)phenyl]oxazolidinones as antibacterial agents
INVENTOR(S): Barbachyn, Michael R.; Thomas, Richard C.; Cleek, Gary J.; Thomasco, Lisa Marie; Gadwood, Robert C.
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9615130	A1	19960523	WO 1995-US12751	19951031
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9538890	A1	19960606	AU 1995-38890	19951031
AU 702733	B2	19990304		
EP 792273	A1	19970903	EP 1995-938148	19951031
EP 792273	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9509673	A	19970930	BR 1995-9673	19951031
CN 1163615	A	19971029	CN 1995-196252	19951031
CN 1046520	B	19991117		
JP 10508844	T2	19980902	JP 1995-516040	19951031
RU 2128660	C1	19990410	RU 1997-110168	19951031
AT 233766	E	20030315	AT 1995-938148	19951031
PT 792273	T	20030630	PT 1995-95938148	19951031
NO 9702222	A	19970514	NO 1997-2222	19970514
US 5952324	A	19990914	US 1997-51466	19970514

PRIORITY APPLN. INFO.: US 1994-339979 A2 19941115
WO 1995-US12751 W 19951031
OTHER SOURCE(S): MARPAT 125:142710
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB [(Azabicyclyl)phenyl]oxazolidinones I (R1 = H, halo, methoxy; R2 = H, alkyl, etc.; X = O, S, etc.; a, b, c, d, e, f = integer) were disclosed as antimicrobial agents. I are effective against a no. of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. An example compd., II, was prepd. II was more effective than vancomycin in a test against Staphylococcus aureus.
IT **179339-76-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of [(azabicyclyl)phenyl]oxazolidinones as biocides)
RN 179339-76-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-2-oxido-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **179339-60-7P 179339-65-2P 179339-75-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [(azabicyclyl)phenyl]oxazolidinones as biocides)
RN 179339-60-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylphenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-65-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1S,4S)-2-thia-5-azabicyclo[2.2.1]hept-5-ylphenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 179339-75-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **179339-57-2P**
RL: BYP (Byproduct); PREP (Preparation)
(prepn. of [(azabicyclyl)phenyl]oxazolidinones as biocides)
RN 179339-57-2 CAPLUS
CN Butanoic acid, [3-[3-fluoro-4-(2-oxa-5-azabicyclo[2.2.1]hept-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl ester, [1S-[1.alpha.,4.alpha.,5(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **179339-56-1P 179339-58-3P 179339-59-4P**
179339-63-0P 179339-64-1P 179339-73-2P
179339-74-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of [(azabicyclyl)phenyl]oxazolidinones as biocides)
RN 179339-56-1 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylphenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-58-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylphenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 179339-59-4 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylphenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-63-0 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1S,4S)-2-thia-5-azabicyclo[2.2.1]hept-5-ylphenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-64-1 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1S,4S)-2-thia-5-azabicyclo[2.2.1]hept-5-ylphenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 179339-73-2 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-74-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-5-[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **179339-66-3P 179339-77-6P 179339-78-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

L5 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
study): PREP (Preparation); USES (Uses)
(prepn. of [(azabicyclyl)phenyl]oxazolidinones as biocides)
RN 179339-66-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[(1S,4S)-2,2-dioxido-2-thia-5-azabicyclo[2.2.1]hept-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-77-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(3aS,6aR)-tetrahydro-2,2-dioxido-1H-thieno[3,4-c]pyrrol-5(3H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179339-78-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:995373 CAPLUS
DOCUMENT NUMBER: 124:201791
TITLE: Preparation of .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides as renin inhibitors.
INVENTOR(S): Goeschke, Richard; Maibaum, Juergen Klaus; Schilling, Walter; Stutz, Stefan; Rigollier, Pascal; Yamaguchi, Yasuchika; Cohen, Nissim Claude; Herold, Peter
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 115 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 678503	A1	19951025	EP 1995-810236	19950407
EP 678503	B1	19990901		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5559111	A	19960924	US 1995-416242	19950404
AT 183997	E	19990915	AT 1995-810236	19950407
ES 2137478	T3	19991216	ES 1995-810236	19950407
FI 9501771	A	19951019	FI 1995-1771	19950412
NO 9501441	A	19951019	NO 1995-1441	19950412
AU 9516421	A1	19951026	AU 1995-16421	19950412
AU 699616	B2	19981210		
ZA 9503051	A	19951018	ZA 1995-3051	19950413
ZA 9503052	A	19951018	ZA 1995-3052	19950413
CA 2147056	AA	19951019	CA 1995-2147056	19950413
ZA 9503050	A	19951108	ZA 1995-3050	19950413
HU 71701	A2	19960129	HU 1995-1078	19950414
HU 74074	A2	19961028	HU 1995-1076	19950414
CZ 287935	B6	20010314	CZ 1995-976	19950414
TW 402582	B	20000821	TW 1995-84103732	19950415
CN 1117960	A	19960306	CN 1995-105037	19950417
IL 113403	A1	20010724	IL 1995-113403	19950417
JP 08081430	A2	19960326	JP 1995-92532	19950418
JP 3240322	B2	20011217		
US 5654445	A	19970805	US 1996-674555	19960702
US 5627182	A	19970506	US 1996-687878	19960725
US 5646143	A	19970708	US 1996-687277	19960725
US 5705658	A	19980106	US 1997-800671	19970214

PRIORITY APPLN. INFO.: CH 1994-1169 A 19940418
US 1995-416242 A3 19950404
US 1996-687277 A3 19960725

OTHER SOURCE(S): MARPAT 124:201791
GI

L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Title compds. [I; R1 = H, OH, alkoxy, cycloalkoxy, alkoxyalkoxy, (amidated or esterified) CO2H; R2 = H, alkyl, cylcoalkyl, alkoxyalkyl, cycloalkoxyalkyl, OH, hydroxyalkoxy, heteroarylalkyl, etc.; R3 = (halogenated) alkyl, alkoxyalkyl, hydroxyalkyl, (5-oxidized) alkylthioalkyl, etc.; R4 = H, alkyl, OH, alkoxy, cycloalkoxy; R3R4 = alkylenedioxy, condensed benzo- or cyclohexeno ring; X = CH2, CHOH; R5 = alkyl, cycloalkyl; R6 = (alkylated alkanoylated) amino; R7 = alkyl, alkenyl, cycloalkyl, aralkyl; R8 = alkyl, cycloalkyl, (esterified or etherified) hydroxyalkyl, (esterified or amidated) carboxyalkyl, etc.], were prepd. Thus, 2(R,S)-methyl-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(p-tert-butylphenyl)octanoic acid N-butylamide hydrochloride was prepd. in several steps starting with 3-isovaleryl-4(R)-benzyloxazolidin-2-one and p-tert-butylbenzyl bromide. I inhibited human plasma renin with IC50 = 10-6-10-10 M, and reduced blood pressure in marmosets at 0.003-0.3 mg/kg i.v.

IT **172966-59-5P 172966-65-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides as renin inhibitors)

RN 172966-59-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172966-65-3 CAPLUS
CN 1,4-Dioxa-8-azaspiro[4.5]decane-6-carboxylic acid, 8-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, methyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **172966-85-7P 172966-87-9P 172966-90-4P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides as renin inhibitors)

RN 172966-85-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[2-(hydroxymethyl)-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 172966-87-9 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-oxa-4,8-diazaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172966-90-4 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[2-[(methoxymethoxy)methyl]-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L5 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:995025 CAPLUS
DOCUMENT NUMBER: 124:117299
TITLE: Preparation of (piperidinophenyl)oxazolidinone derivatives as antimicrobial agents
INVENTOR(S): Yamada, Hiroyoshi; Munesada, Kiyotaka; Taniguchi, Mikio
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9525106	A1	19950921	WO 1995-US2972	19950314
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 08073455	A2	19960319	JP 1994-235167	19940929
CA 2183972	AA	19950921	CA 1995-2183972	19950314
AU 9520999	A1	19951003	AU 1995-20999	19950314
AU 681953	B2	19970911		
EP 750618	A1	19970102	EP 1995-913624	19950314
EP 750618	B1	20030219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1143961	A	19970226	CN 1995-192083	19950314
JP 09512785	T2	19971222	JP 1995-523655	19950314
AT 232862	E	20030315	AT 1995-913624	19950314
PT 750618	T	20030630	PT 1995-95913624	19950314
ES 2191048	T3	20030901	ES 1995-913624	19950314
US 5668286	A	19970916	US 1996-714117	19960909

PRIORITY APPLN. INFO.: JP 1994-43949 A 19940315
JP 1994-146565 A 19940628
JP 1994-235167 A 19940929
WO 1995-US2972 W 19950314

OTHER SOURCE(S): MARPAT 124:117299
GI

L5 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II



III

AB Novel oxazolidinone derivs. represented by chem. formula (I; R = H, alkyl, cycloalkyl, NH2, alkylamino, dialkylamino, alkoxy, haloalkyl; R1, R3 = H, alkyl cycloalkyl, O-(un)substituted hydroxyalkyl or carboxyalkyl, CHO, hydroxyalkanoyl, alkanoyl, acyloxymethoxycarbonyl; X, Y = H, halo; R4, R5 = H, alkyl, alkoxy, alkylthio, O-(un)substituted hydroxyalkyl or hydroxyalkoxy, (un)substituted NH2, N-(un)substituted N-(aminomethylene)amino, (un)substituted carbamoyl, formyl-, O-(un)substituted hydroxyalkanoyl-, alkoxycarbonyl-, acyloxymethoxycarbonyl-, or O-(un)substituted (carboxyalkanoyl)alkyl, or ethylene ketal thereof; or R4R5 = O, (un)substituted NH or :CH2, S, (un)substituted 5- or 6-membered hetero ring having 1-3 heteroatoms selected from N, O, and S; n = 0,1) or pharmaceutically acceptable salts thereof, having high antimicrobial activity for preventing and treating infectious diseases, are prepd. Antimicrobial compns. contain said derivs. or salts thereof as active ingredients. Thus, 3,4-difluoronitrobenzene was condensed with piperidine in the presence of (Me2CH)2NEt in EtOAc to 3-fluoro-4-piperidinonitrobenzene, which was hydrogenated in the presence of 10% Pd-C under H atm. in EtOAc to the amine and acylated by benzyloxycarbonyl chloride in the presence of NaHCO3 in THF to give the benzyl carbonate (II). The latter compd. was treated with BuLi in hexane/THF at -78.degree. and cyclocondensed with (R)-(-)-glycidyl butyrate at the same temp. to give the (hydroxymethyl)oxazolidinone (III; R6 = OH, R7 = H), which was tosylated with tosyl chloride in pyridine at room temp. followed by azidolysis of the resulting tosylate III (R6 = OSO2C6H4Me-p, R7 = H) with NaN3 in DMF at 65.degree. to the azide III (R6 = N3, R7 = H) and hydrogenation in the presence of 10% Pd-C in EtOAc contg. Ac2O and pyridine under H atm. to give the title compd. III (R6 = NHAc, R7 = H). III (R6 = NHAc, R7 = EtO2C) showed min. inhibitory concn. of 8, 2, 2, and 1 .mu.g/mL against Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes, and Mycobacterium tuberculosis, resp.

IT **172966-59-5P 172966-65-3P 172966-85-7P**
172966-87-9P 172966-90-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (piperidinophenyl)oxazolidinone derivs. as antimicrobial agents)

L5 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 172966-59-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172966-65-3 CAPLUS
CN 1,4-Dioxa-8-azaspiro[4.5]decane-6-carboxylic acid, 8-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 172966-85-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[2-(hydroxymethyl)-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 172966-87-9 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-oxa-4,8-diazaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 172967-24-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172967-25-8 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172967-26-9 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 172966-90-4 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[2-[(methoxymethoxy)methyl]-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



IT **172967-22-5P 172967-23-6P 172967-24-7P**
172967-25-8P 172967-26-9P 172967-27-0P
172967-28-1P 172967-29-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of (piperidinophenyl)oxazolidinone derivs. as antimicrobial agents)
RN 172967-22-5 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(1-oxa-4,8-diazaspiro[4.5]dec-8-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172967-23-6 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[4-[(phenylmethoxy)acetyl]-1-oxa-4,8-diazaspiro[4.5]dec-8-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 172967-27-0 CAPLUS
CN Acetamide, N-[[3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-(phenylmethoxy)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172967-28-1 CAPLUS
CN Acetamide, N-[[3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172967-29-2 CAPLUS
CN Acetamide, N-[[3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-fluoro-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:298621 CAPLUS
DOCUMENT NUMBER: 120:298621
TITLE: [[(Aminomethyl)oxo]oxazolidinyl]arylbenzene antibacterial agents
INVENTOR(S): Carlson, Randall K.; Park, Chung Ho; Gregory, Walter A.
PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USA
SOURCE: U.S., 28 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5254577	A	19931019	US 1991-811400	19911220

PRIORITY APPLN. INFO.: US 1991-811400 19911220
OTHER SOURCE(S): MARPAT 120:298621
GI



I

AB The title compds. [I; A = (un)substituted Ph; B = N3, aminocarbonyl deriv., etc.], active against Gram-pos. bacteria including multiple antibiotic-resistant strains of Staphylococcus and Streptococcus, are prepd. and I-contg. formulations presented. Thus, 4-phenylphenyl isocyanate was cyclized with L-glycidyl butyrate, treated with p-toluenesulfonyl chloride, detosylate, condensed with NaN3, the azide hydrogenated to the corresponding amine, and the amine acetylated with AcCl, producing I (A = Ph, B = NHAc) (II), m.p. 226-227.degree.. II demonstrate MIC against Staphylococcus aureus of 0.5 .mu.g/mL and demonstrated s.c. administration in-vivo activity against S. aureus in an acute, lethal mouse model of 2 mg/kg.

IT **128311-91-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antibiotic activity)

RN 128311-91-1 CAPLUS
CN Acetamide, N-[[3-[4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L5 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:560265 CAPLUS
DOCUMENT NUMBER: 119:160265
TITLE: Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
INVENTOR(S): Barbachyn, Michael Robert; Brickner, Steven Joseph
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9309103	A1	19930513	WO 1992-US8267	19921005
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9226898	A1	19930607	AU 1992-26898	19921005
AU 667198	B2	19960314		
EP 610265	A1	19940817	EP 1992-921324	19921005
EP 610265	B1	19961227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
JP 07500603	T2	19950119	JP 1992-508405	19921005
AT 146783	E	19970115	AT 1992-921324	19921005
JP 3176626	B2	20010618	JP 1993-508405	19921005
US 5929248	A	19990727	US 1997-842282	19970423

PRIORITY APPLN. INFO.: US 1991-786107 A2 19911101
US 1992-831213 A2 19920207
WO 1992-US8267 A 19921005
US 1994-233903 A3 19940428
US 1995-466955 A3 19950606
OTHER SOURCE(S): MARPAT 119:160265
GI



I

AB Title compds. I (R1, R2 = H, F, Cl, F3O, MeO, provided that only 1 of R1, R2 is H; R3 = Ph, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, (substituted) indolyl, etc.; R4 = H, (substituted) C1-12 alkyl, etc.) useful as antibacterials (no data), are prepd. (.+-.)-5-(Azidomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone (prepn. given) in MeOH was hydrogenated to give the amine which in CH2Cl2, was combined with Ac2O to give (.+-.)-I (R1 = R2 = F, R3 = 3-pyridyl, R4 = Me).

IT **149523-98-8P 149523-99-9P 149524-00-5P**
149524-01-6P 149524-22-1P 149524-23-2P
149524-24-3P 149524-25-4P 183124-48-3P
183124-73-4P 183124-74-5P 183124-76-7P

L5 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
183124-96-1P 183124-98-3P 183125-00-0P
183125-02-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antibacterial)

RN 149523-98-8 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(1H-indol-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 149523-99-9 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(1-methyl-1H-indol-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 149524-00-5 CAPLUS
CN Acetamide, N-[[3-[4-(6-benzothiazolyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 149524-01-6 CAPLUS
CN Acetamide, N-[[3-[4-(6-benzoxazolyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 149524-22-1 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(1H-indol-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 149524-23-2 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(1-methyl-1H-indol-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 149524-24-3 CAPLUS
CN Acetamide, N-[[3-[4-(6-benzothiazolyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 149524-25-4 CAPLUS
CN Acetamide, N-[[3-[4-(6-benzoxazolyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-48-3 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(6-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-73-4 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(3-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-74-5 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(4-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 183124-76-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-96-1 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(3-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-98-3 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(4-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 183125-00-0 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(6-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183125-02-2 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1990:572003 CAPLUS
DOCUMENT NUMBER: 113:172003
TITLE: 5-(Aminomethyl)-3-(4-arylphenyl)oxazolidin-2-one derivatives useful as antibacterial agents
INVENTOR(S): Carlson, Randall Kent; Gregory, Walter Adelman; Park, Chung Ho
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 352781	A2	19900131	EP 1989-113837	19890727
EP 352781	A3	19900711		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4948801	A	19900814	US 1988-225809	19880729
DK 8903743	A	19900130	DK 1989-3743	19890728
NO 8903076	A	19900130	NO 1989-3076	19890728
FI 8903618	A	19900130	FI 1989-3618	19890728
JP 02124877	A2	19900514	JP 1989-194442	19890728
JP 2899319	B2	19990602		
ZA 8905778	A	19910327	ZA 1989-5778	19890728
HU 58062	A2	19920128	HU 1989-3901	19890728
CA 1337526	A1	19951107	CA 1989-607006	19890728
AU 8939115	A1	19900201	AU 1989-39115	19890731
AU 622465	B2	19920409		
US 5043443	A	19910827	US 1990-558131	19900724
US 5130316	A	19920714	US 1990-558129	19900725
US 5254577	A	19931019	US 1992-929452	19920814

PRIORITY APPLN. INFO.: US 1988-225809 19880729
US 1990-558126 19900724

OTHER SOURCE(S): MARPAT 113:172003
GI



I



II

L5 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB The title compds. [I; Ar = (substituted) pyridyl, Ph, di- or triazinyl, azolyl; B = amino, acylamino, N3; when B = NH2, Ar .noteq. Ph substituted with halo, CF3] were prepd. Thus, an oxazolidine deriv. II, prepd. starting from 4-biphenyl isocyanate and (l)-glycidyl butyrate via I (Ar = Ph, B = OH) had an oral ED50 of 2.9 ng/kg against Staphylococcus aureus in mice.

IT **128311-91-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antibacterial)

RN 128311-91-1 CAPLUS

CN Acetamide, N-[[3-[4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.